GWG (GWGHQ) 10-Q 6 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	5-May-14
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'GWG Holdings, Inc.	'
Entity Central Index Key	'0001522690	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	9,124,000

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
A S S E T S	'	'
Cash and cash equivalents	$28,083,299	$33,449,793
Restricted cash	2,853,763	5,832,970
Investment in life settlements, at fair value	254,503,535	234,672,794
Other assets	2,136,666	1,424,919
TOTAL ASSETS	287,577,263	275,380,476
LIABILITIES	'	'
Revolving credit facility	79,000,000	79,000,000
Series I Secured notes payable	28,602,238	29,275,202
Renewable Secured Debentures	145,989,431	131,646,062
Interest payable	8,399,192	7,209,408
Accounts payable and accrued expenses	1,293,139	1,343,952
Deferred taxes, net	6,720,316	7,675,174
TOTAL LIABILITIES	270,004,316	256,149,798
CONVERTIBLE, REDEEMABLE PREFERRED STOCK (par value $0.001; shares authorized 40,000,000; shares issued and outstanding 3,478,219 and 3,394,916; liquidation preference of $26,087,000 and $25,462,000, respectively)	25,036,056	24,722,693
STOCKHOLDERS' EQUITY	'	'
Common stock (par value $0.001: shares authorized 210,000,000; shares issued and outstanding is 9,124,000 on both March 31, 2014 and December 31, 2013)	9,124	9,124
Additional paid-in capital	2,867,514	2,937,438
Accumulated deficit	-10,339,747	-8,438,577
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	-7,463,109	-5,492,015
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$287,577,263	$275,380,476

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Balance Sheets [Abstract]	'	'
Convertible redeemable preferred stock, par value	$0.00	$0.00
Convertible redeemable preferred stock, shares authorized	40,000,000	40,000,000
Convertible redeemable preferred stock, shares issued	3,478,219	3,394,916
Convertible redeemable preferred stock, shares outstanding	3,478,219	3,394,916
Convertible redeemable preferred stock, liquidation preference	$26,087,000	$25,462,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	210,000,000	210,000,000
Common stock, shares issued	9,124,000	9,124,000
Common stock, shares outstanding	9,124,000	9,124,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
REVENUE	'	'
Gain on life settlements, net	$5,516,205	$8,340,356
Interest and other income	7,367	167,670
TOTAL REVENUE	5,523,572	8,508,026
EXPENSES	'	'
Employee compensation and benefits	968,746	1,937,420
Legal and professional fees	325,298	437,290
Interest expense	6,326,548	4,467,215
Other expenses	759,008	1,033,144
TOTAL EXPENSES	8,379,600	7,875,069
INCOME (LOSS) BEFORE INCOME TAXES	-2,856,028	632,957
INCOME TAX EXPENSE (BENEFIT)	-954,858	565,823
NET INCOME (LOSS)	-1,901,170	67,134
Accretion of preferred stock to liquidation value	-125,714	-257,763
LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	($2,026,884)	($190,629)
NET INCOME (LOSS) PER COMMON SHARE (BASIC AND DILUTED)	'	'
Net income (loss)	($0.21)	$0.01
Accretion of preferred stock to liquidation value	($0.01)	($0.03)
Net loss per share attributable to common shareholders	($0.22)	($0.02)
WEIGHTED AVERAGE SHARES OUTSTANDING	'	'
Basic and diluted	9,124,000	9,989,000

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net income (loss)	($1,901,170)	$67,134
Adjustments to reconcile net income (loss) to net cash flows from operating activities:	'	'
Life settlements - change in fair value	-11,358,913	-11,494,725
Amortization of deferred financing and issuance costs	353,657	1,093,747
Deferred income taxes	-954,858	563,874
Convertible, redeemable preferred stock dividends payable	192,340	83,702
(Increase) decrease in operating assets:	'	'
Other assets	-251,846	551,174
Increase in operating liabilities:	'	'
Accounts payable and other accrued expenses	1,277,826	1,290,756
NET CASH FLOWS USED IN OPERATING ACTIVITIES	-12,642,964	-7,844,338
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Investment in life settlements	-8,271,203	-9,913,049
Proceeds from settlement of life settlements	'	1,490,000
NET CASH FLOWS USED IN INVESTING ACTIVITIES	-8,271,203	-8,423,049
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Net proceeds from revolving credit facility	'	8,000,000
Payments for redemption of Series I Secured notes payable	-868,303	-1,507,824
Proceeds from issuance of Renewable Secured Debentures	18,365,657	23,850,794
Payments for issuance cost and redemption of Renewable Secured Debentures	-4,928,888	-2,303,268
Proceeds (payments) from restricted cash	2,979,207	-4,531,108
Issuance of preferred stock	'	-186,669
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	15,547,673	23,321,925
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	-5,366,494	7,054,538
Cash and cash equivalents	'	'
BEGINNING OF PERIOD	33,449,793	27,497,044
END OF PERIOD	28,083,299	34,551,582
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION	'	'
Interest and preferred dividends paid	4,250,000	3,298,000
Series I Secured notes:	'	'
Accrued interest and commissions payable added to principal	65,000	61,000
Renewable Secured Debentures:	'	'
Accrued interest and commissions payable added to principal	119,000	41,000
Convertible, redeemable preferred stock:	'	'
Accretion of convertible, redeemable preferred stock to redemption value	126,000	258,000
Conversion of dividends payable	$188,000	$84,000

Nature_of_Business_and_Summary

Nature of Business and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Nature of Business and Summary of Significant Accounting Policies [Abstract]	'
Nature of business and summary of significant accounting policies	'
	( 1 )   Nature of business and summary of significant accounting policies
	Nature of business - GWG Holdings, Inc. and subsidiaries, located in Minneapolis, Minnesota, facilitates the purchase of life insurance policies for its own investment portfolio through its wholly owned subsidiary, GWG Life Settlements, LLC (GWG Life), and its subsidiaries, GWG Trust (Trust), GWG DLP Funding II, LLC (DLP II) and its wholly owned subsidiary, GWG DLP Master Trust II (the Trust II). Our wholly owned subsidiary, GWG Broker Services, LLC (Broker Services), was formed to earn fees for brokering policy transactions between market participants. Our wholly owned subsidiary United Lending, LLC (United Lending) and its wholly owned subsidiary United Lending SPV, LLC (United Lending SPV) were formed to finance life settlement premiums and policy loans.  All of these entities are legally organized in Delaware. Unless the context otherwise requires or we specifically so indicate, all references in this report to "we", "us", "our", "our Company", "GWG", or the "Company" refer to these entities collectively. GWG Member, LLC, a wholly owned subsidiary formed November 2010 to facilitate the acquisition of policies, has not commenced operations as of December 31, 2013. The entities were legally organized in Delaware and are collectively referred herein to as GWG, or the Company.
	Basis of presentation - The condensed consolidated balance sheet as of March 31, 2014, the condensed consolidated statements of operations for the three months ended March 31, 2014 and 2013, and the condensed consolidated statements of cash flows for the three months ended March 31, 2014 and 2013, and the related information presented in these notes, have been prepared by management in accordance with U.S. generally accepted accounting principles (“GAAP”)  for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X, without audit. To the extent that information and notes required by U.S. generally accepted accounting principles for complete financial statements are contained in or are consistent with the consolidated audited financial statements in the Company’s Form 10-K for the year ended December 31, 2013, such information and notes have not been duplicated herein . In the opinion of management, all adjustments considered necessary for a fair presentation of results have been included. The condensed consolidated balance sheet at December 31, 2013 was derived from the audited consolidated financial statements as of that date. Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Special Financial Report on Form 10-K for the year ended December 31, 2013.
	Use of estimates - The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making
	judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. The most significant estimates with regard to these consolidated financial statements relates to (1) the determination of the assumptions used in estimating the fair value of the investment in life insurance policies, and (2) the value of deferred tax assets and liabilities.
	Life settlements - ASC 325-30, Investments in Insurance Contracts, allows a reporting entity the election to account for its investments in life settlements using either the investment method or the fair value method. The election shall be made on an instrument-by-instrument basis and is irrevocable. Under the investment method, an investor shall recognize the initial investment at the purchase price plus all initial direct costs. Continuing costs (policy premiums and direct external costs, if any) to keep the policy in force shall be capitalized. Under the fair value method, an investor shall recognize the initial investment at the purchase price. In subsequent periods, the investor shall remeasure the investment at fair value in its entirety at each reporting period and shall recognize the change in fair value in current period income net of premiums paid. The Company uses the fair value method to account for all life settlements.
	The Company recognizes realized gains (revenue) from life settlement contracts upon one of the two following events:
		1)	Receipt of death notice or verified obituary of insured
		2)	Sale of policy and filing of change of ownership forms and receipt of payment
	The Company recognizes the difference between the death benefits and carrying values of the policy when an insured event has occurred and the Company determines that settlement and ultimate collection of the death benefits is realizable and reasonably assured. Revenue from a transaction must meet both criteria in order to be recognized. In an event of a sale of a policy the Company recognizes gain or loss as the difference between the sale price and the carrying value of the policy on the date of the receipt of payment on such sale.
	Deposits and initial direct costs advanced on unsettled policy acquisitions are recorded as other assets until policy ownership has been transferred to the Company.  Such deposits and direct cost advances were $0 and $201,000 at March 31, 2014 and December 31, 2013, respectively.
	Deferred financing and issuance costs – Costs incurred to obtain financing under the revolving credit facility, as described in note 6, have been capitalized and are amortized using the straight-line method over the term of the revolving credit facility. Amortization of deferred financing costs was $89,000 and $187,000 for the three-month periods ended March 31, 2014 and 2013, respectively. The future amortization is expected to be $268,000 for the nine months ending December 31, 2014.  The Series I Secured notes payable, as described in note 7, are reported net of issuance costs, sales commissions and other direct expenses, which are amortized using the interest method over the term of each respective borrowing. The Renewable Secured Debentures, as described in note 8, are reported net of issuance costs, sales commissions and other direct expenses, which are amortized using the interest method over the term of each respective borrowing. The Series A preferred stock, as described in note 9, is reported net of issuance costs, sales commissions, including the fair value of warrants issued, and other direct expenses, which are amortized using the interest method as interest expense over the three-year redemption period.
	Earnings (loss) per share - Basic per share earnings (loss) attributable to non-redeemable interests is calculated using the weighted-average number of shares outstanding during the period. Diluted earnings per share is calculated based on the potential dilutive impact, if any, of the Company’s convertible, redeemable preferred stock, and outstanding warrants, and stock options.
	Subsequent events - Subsequent events are events or transactions that occur after the balance sheet date but before consolidated financial statements are issued. The Company recognizes in the consolidated financial statements the effects of all subsequent events that provide additional evidence about conditions that existed at the date of the balance sheet, including the estimates inherent in the process of preparing the consolidated financial statements. The Company’s consolidated financial statements do not recognize subsequent events that provide evidence about conditions that did not exist at the date of the balance sheet but arose after the balance sheet date and before the consolidated financial statements are available to be issued. The Company evaluates subsequent events and transactions that occur after the balance sheet date up to the date that the consolidated financial statements are filed for potential recognition or disclosure.
	Recently adopted pronouncements - Pronouncements issued by the FASB or other authoritative accounting standards groups with future effective dates are either not applicable or are not expected to be significant to the Company.

Restrictions_on_Cash

Restrictions on Cash	3 Months Ended
	Mar. 31, 2014
Restrictions on Cash [Abstract]	'
Restrictions on cash	'
	( 2 )       Restrictions on cash
	The Company is required by its lenders to maintain collection and escrow accounts. These accounts are used to fund the acquisition, pay annual premiums of insurance policies, pay interest and other charges under the revolving credit facility, and collect policy benefits. DZ Bank AG, as agent for Autobahn Funding Company, LLC, the lender for the revolving credit facility as described in note 6, authorizes the disbursements from these accounts. At March 31, 2014 and December 31, 2013 there was a balance of $2,854,000, and $5,833,000, respectively, maintained in these restricted cash accounts.

Investment_in_Life_Insurance_P

Investment in Life Insurance Policies	3 Months Ended
	Mar. 31, 2014
Investment in Life Insurance Policies [Abstract]	'
Investment in life insurance policies	'
	( 3 )      Investment in life insurance policies
	The life insurance policies (Level 3 fair value measurements) are valued based on unobservable inputs that are significant to the overall fair value measurement. Changes in the fair value of these instruments are recorded in gain or loss on life insurance policies in the consolidated statements of operations (net of the cash premiums paid on the policies). The fair value is determined on a discounted cash flow basis that incorporates life expectancy assumptions.  Life expectancy reports have been obtained from widely accepted life expectancy providers. The discount rate incorporates current information about market interest rates, the credit exposure to the insurance company that issued the life insurance policy and our estimate of the risk premium an investor in the policy would require. As a result of management’s analysis, discount rate of 11.69% was applied to the portfolio as of March 31, 2014 and December 31, 2013.
	A summary of the Company’s life insurance policies accounted for under the fair value method and their estimated maturity dates, based on remaining life expectancy is as follows:
		As of March 31, 2014								As of December 31, 2013
	Years Ending December 31,	Number of Contracts			Estimated Fair Value			Face Value		Number of Contracts		Estimated Fair Value		Face Value
	2014		-		$	-		$	-		-	$	-	$	-
	2015		4			5,238,000			6,750,000		4		5,065,000		6,750,000
	2016		11			10,610,000			16,800,000		8		8,174,000		13,750,000
	2017		29			32,186,000			59,916,000		25		33,345,000		63,916,000
	2018		30			34,573,000			71,017,000		33		37,243,000		80,318,000
	2019		41			43,654,000			113,795,000		34		32,844,000		89,295,000
	2020		37			30,497,000			81,014,000		34		27,741,000		75,644,000
	Thereafter		134			97,746,000			422,648,000		125		90,261,000		410,975,000
	Totals		286			254,504,000			771,940,000		263	$	234,673,000	$	740,648,000
	The Company recognized death benefits of $0 and $4,000,000 during the three-month periods ended March 31, 2014 and 2013, respectively, related to policies with a carrying value of $0 and $1,490,000, respectively.  The company recorded realized gains of $0 and $2,510,000 on such policies.
	Reconciliation of gain on life settlements:
	Three Months Ended:	March 31,			March 31,
		2014			2013
	Change in fair value	$	11,359,000		$	11,495,000
	Premiums and other annual fees		(5,843,000	)		(5,665,000	)
	Policy maturities		-			2,510,000
	Gain on life settlements, net	$	5,516,000		$	8,340,000
	The estimated expected premium payments to maintain the above life insurance policies in force through 2018, assuming no mortalities, are as follows:
	Years Ending December 31,
	Nine months ending December 31 ,2014	$	17,882,000
	2015		26,078,000
	2016		28,550,000
	2017		32,109,000
	2018		35,155,000
		$	139,774,000
	Management anticipates funding the estimated premium payments as noted above with proceeds from the DZ Bank revolving credit facility and through additional debt and equity financing as well as from cash proceeds from maturities of life insurance policies. The proceeds of these capital sources are also intended to be used for the purchase, financing, and maintenance of additional life insurance policies.

Fair_Value_Definition_and_Hier

Fair Value Definition and Hierarchy	3 Months Ended
	Mar. 31, 2014
Fair Value Definition and Hierarchy [Abstract]	'
Fair value definition and hierarchy	'
	( 4 )       Fair value definition and hierarchy
	ASC 820 establishes a hierarchal disclosure framework which prioritizes and ranks the level of market price observability used in measuring assets and liabilities at fair value. Market price observability is affected by a number of factors, including the type of investment, the characteristics specific to the investment and the state of the marketplace including the existence and transparency of transactions between market participants. Assets and liabilities with readily available active quoted prices or for which fair value can be measured from actively quoted prices in an orderly market generally will have a higher degree of market price observability and a lesser degree of judgment used in measuring fair value. ASC 820 establishes a three-level valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.
	The hierarchy is broken down into three levels based on the observability of inputs as follows:
	●	Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.  Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.
	●	Level 2 - Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
	●	Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
	The availability of observable inputs can vary by types of assets and liabilities and is affected by a wide variety of factors, including, for example, whether instrument is established in the marketplace, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by management in determining fair value is greatest for assets and liabilities categorized in Level 3.
	Level 3 Valuation Process
	The estimated fair value of the Company’s life settlements are determined on a quarterly basis by the Company’s portfolio management committee, taking into consideration changes in discount rate assumptions, estimated premium payments and life expectancy assumptions, as well as any changes in economic and other relevant conditions.  These inputs are then used to estimate the discounted cash flows using the MAPS probabilistic portfolio pricing model, which estimates the cash flows using various different probabilities and scenarios.  The valuation process includes a review by senior management as of each valuation date.  Management also engages a third party expert to independently test the accuracy of the valuations using the inputs provided by management.
	Life insurance policies represent financial instruments recorded at fair value on a recurring basis. The following table reconciles the beginning and ending fair value of the Company’s Level 3 investments in life insurance policies for the three-month periods ending March 31, as follows:
				2014				2013
	Beginning balance		$	234,673,000			$	164,317,000
	Purchases			8,472,000				10,698,000
	Maturities (acquisition cost basis)			-				(1,490,000	)
	Gross unrealized gains			11,359,000				11,616,000
	Gross unrealized losses			-				(121,000	)
	Ending balance		$	254,504,000			$	185,020,000
	The fair value of a portfolio of life insurance policies is based on information available to the Company at the reporting date. Fair value is based upon a discounted cash flow model that incorporates life expectancy estimate assumptions. Life expectancy estimates are obtained from independent, third-party, widely accepted life expectancy estimate providers at policy acquisition. The life expectancy values of each insured, as determined at policy acquisition, are rolled down monthly for the passage of time by the MAPS actuarial software the Company uses for ongoing valuation of its portfolio of life insurance policies. The discount rate incorporates current information about discount rates applied by other reporting companies owning portfolios of life insurance policies, discount rates observed in the life insurance secondary market, market interest rates, the credit exposure to the insurance company that issued the life insurance policy and management’s estimate of the risk premium a purchaser would require to receive the future cash flows derived from our portfolio of life insurance policies.
	On January 22, 2013, one of the independent medical actuarial underwriting firms we utilize, 21st Services, announced advancements in its underwriting methodology, resulting in revised estimated life expectancy mortality tables for life settlement transactions. We were advised by 21st Services that the changes are very granular and relate to both specific medical conditions and lifestyles of insureds. These changes were the result of the application of additional medical information gathered by 21st Services over a period of time, and which were applied to the inputs and methodologies used to develop the actuarial life expectancies. While we do not believe these revised methodologies indicate the previous estimated life expectancies were inaccurate, we believe the revised methodologies provide additional information that should be considered in updating our estimate of the life expectancies of the insureds within our portfolio. Based upon our evaluation and analysis of data made available by 21st Services, as well as information regarding the insureds within our portfolio, we have estimated the impact of the changes in 21st Services’ methodologies for determining life expectancies on a policy-by-policy basis within our portfolio as of December 31, 2012 and applied such changes to the life expectancy inputs used to estimate fair value. We have adjusted the original life expectancies provided by 21st Services based on four factors, the impact of each analyzed individually for each insured in the GWG portfolio. The four factors are gender, anti-selection, age, and primary impairment. GWG applied this set of adjustments to all 21st Services life expectancy reports used in valuation of the portfolio as of December 31, 2012. At that time, the portfolio contained 211 policies on 194 insured lives. Of those 211 policies, 199 were valued using a 21st Services life expectancy report as part of the pricing life expectancy estimate calculation. While the analysis and adjustments were applied on an individual policy basis, the result was an average overall increase in the original life expectancy estimates of 8.67%. We have a standard practice of obtaining two third-party life expectancy estimates for each policy in our portfolio. As a result, the effective change in life expectancy on the portfolio as of December 31, 2012 was an average of approximately 4.33%, which resulted in an aggregate decrease in the fair value of our life settlements portfolio of $12.4 million as of December 31, 2012. Life expectancy reports by their very nature are estimates.
	During 2013, we sought to update our life expectancy estimates from all four of the major independent third-party medical-actuarial underwriting firms (including 21st Services) with updated medical records on all of the 211 policies we originally used a life expectancy report from 21st Services. As of December 31, 2013, we had successfully procured new life expectancy reports on 176 of the 211 policies owned as of December 31, 2012. We experienced ten mortalities in 2013 for which no updated life expectancy reports were necessary. We also had two small face policies in our portfolio for which we did not update life expectancy reports. Accordingly, as of March 31, 2014 we had updated our life expectancy estimates based on updated life expectancy reports on all but 12 policies (covering 10 people) in our portfolio that we are still seeking to update.
	In order to assess the reasonableness of our adjustments, made effective December 31, 2012, we compared the life expectancy estimates including any adjustments used on December 31, 2012 to the updated life expectancy estimates used on December 31, 2013. Because an additional year has elapsed since the December 31, 2012 date, the older set of adjusted life expectancy estimates were “rolled down” to shorter numbers based on an actuarial calculation to make them comparable to the updated life expectancy estimates used on December 31, 2013. The average amount of roll down to account for the 12-month passage of time was eight and one-half months.
	We concluded that our the adjustments we made a year ago were reasonable when we the compared the rolled down life expectancy estimates from December 31, 2012 to the updated life expectancy estimates on December 31, 2013. The average rolled down life expectancy estimate from December 31, 2012 is 80.9 months. The average updated life expectancy estimate obtained from updated life expectancy reports as of December 31, 2013 is 79.4 months, shorter by one and one- half months. We see no need to make any further adjustments to our life expectancy estimates at this time.
	The fair value of life insurance policies is estimated using present value calculations of estimated cash flows based on the data specific to each individual life insurance policy.  Estimated future policy premium payments are calculated based on the terms of the policy and the premium payment history. The following summarizes the unobservable inputs utilized in estimating the fair value of the portfolio of life insurance policies:
			As of				As of
			March 31,				December 31,
			2014				2013
	Weighted average age of insured			82.3				82.1
	Weighted average life expectancy, months*			84.3				87
	Average face amount per policy		$	2,699,000			$	2,816,000
	Discount rate			11.69	%			11.69	%
	* Standard life expectancy as adjusted for insured’s specific circumstances.
	These assumptions are, by their nature, inherently uncertain and the effect of changes in estimates may be significant. The techniques used in estimating the present value of estimated cash flows are derived from valuation techniques generally used in the industry that include inputs for the asset that are not based on observable market data. The extent to which the fair value could reasonably vary in the near term has been quantified by evaluating the effect of changes in significant underlying assumptions used to estimate the fair value. If the life expectancy estimates were increased or decreased by four and eight months on each outstanding policy and the discount factors were increased or decreased by 1% and 2%, while all other variables are held constant, the fair value of the investment in life insurance policies would increase or (decrease) by the amounts summarized below:
			Changes in fair value of life insurance policies
	Change in life expectancy estimates		plus 8				minus			plus				minus
			months				8 months			4 months				4 months
	31-Mar-14			$	(36,833,000	)		$	38,756,000		$	(18,658,000	)		$	19,145,000
	31-Dec-13			$	(34,382,000	)		$	36,152,000		$	(17,417,000	)		$	17,865,000
	Change in discount rate		plus 2%					minus 2%			plus 1%				minus 1%
	31-Mar-14			$	(23,949,000	)		$	28,161,000		$	(12,446,000	)		$	13,496,000
	31-Dec-13			$	(22,944,000	)		$	27,063,000		$	(11,933,000	)		$	12,959,000
	Other Fair Value Considerations
	Carrying value of receivables, prepaid expenses, accounts payable and accrued expenses approximate fair value due to their short-term maturities and low credit risk. The estimated fair value of the Company’s Series I Secured notes payable and Renewable Secured Debentures is approximately $180,912,000 based on a weighted-average market interest rate of 7.09% based on an income approach, the combined face value of these notes is $178,289,000 as of March 31, 2014.  The carrying value of the revolving credit facility reflects interest charged at the commercial paper rate plus an applicable margin. The margin represents our credit risk, and the strength of the portfolio of life insurance policies collateralizing the debt. The overall rate reflects market, and the carrying value of the revolver approximates fair value. All of the financial instruments are level 3 fair value measurements.
	The Company has issued warrants to purchase common stock in connection with the issuance of its convertible, redeemable preferred stock. Warrants were determined by the Company as permanent equity. The fair value measurements associated with the warrants, measured at issuance represent level 3 instruments.
	As of March 31, 2014:
	Month issued		Warrants				Fair value			Risk				Volatility			Term
			issued				per share			free rate
	Dec-11			137,874			$	0.11			0.42	%			25.25	%	3 years
	Mar-12			76,260			$	0.26			0.38	%			36.2	%	3 years
	Jun-12			323,681			$	0.58			0.41	%			47.36	%	3 years
	Jul-12			289,093			$	0.58			0.41	%			47.36	%	3 years
	Sep-12			5,000			$	0.36			0.31	%			40.49	%	3 years
				831,908
	Volatility is based upon the weekly percentage change in the stock price of selected comparable insurance companies. In June 2012, we evaluated the comparable companies used, and made certain changes to those used. The percentage change is calculated on the average price of those selected stocks at the weekly close of business for the year preceding the balance sheet date. We compare annual volatility based on this weekly information.

Notes_Receivable_from_Related_

Notes Receivable from Related Parties	3 Months Ended
	Mar. 31, 2014
Notes Receivable from Related Parties [Abstract]	'
Notes receivable from related parties	'
	( 5 )       Notes receivable from related parties
	As of March 31, 2014 and December 31, 2013, the Company had receivables totaling $5,000,000 due from an affiliate, Opportunity Finance, LLC, which were fully reserved. Opportunity Finance ceased operations in 2008.

Credit_Facilities

Credit Facilities	3 Months Ended
	Mar. 31, 2014
Credit facilities and Series I Secured Notes Payable and Renewable Secured Debentures [Abstract]	'
Credit facilities	'
	( 6 )       Credit facilities
	Revolving credit facility – Autobahn Funding Company LLC
	On July 15, 2008, DLP II and United Lending entered into a revolving credit facility pursuant to a Credit and Security Agreement (Agreement) with Autobahn Funding Company LLC (Autobahn), providing the Company with a maximum borrowing amount of $100,000,000. Autobahn is a commercial paper conduit that issues commercial paper to investors in order to provide funding to DLP II and United Lending.  DZ Bank AG acts as the agent for Autobahn. The original Agreement was to expire on July 15, 2013.  On January 29, 2013, Holdings, together with GWG Life and DLPII, entered into an Amended and Restated Credit and Security Agreement with Autobahn Funding Company LLC, extending the facility expiration date to December 31, 2014, and removing United Lending as a party to the renewed Credit and Security Agreement.  The amount outstanding under this facility as of both March 31, 2014 and December 31, 2013 was $79,000,000.
	The Agreement requires DLP II to pay, on a monthly basis, interest at the commercial paper rate plus an applicable margin, as defined in the Agreement. The effective rate was 6.21% and 6.19% at March 31, 2014 and December 31, 2013, respectively.  The weighted average effective interest rate was 6.22% and 5.86% (excluding the unused line fee) for the three months ended March 31, 2014 and 2013, respectively.  The Agreement also requires payment of an unused line fee on the unfunded amount under the revolving credit facility. The note is secured by substantially all of DLP II assets which consist primarily of life insurance policies.
	The Agreement has certain financial and nonfinancial covenants. The Company was in compliance with these covenants at March 31, 2014 and December 31, 2013. The Agreement generally prohibits the Company from:
	●	changing its corporate name, offices, and jurisdiction of incorporation
	●	changing any deposit accounts or payment instructions to insurers;
	●	changing any operating policies and practices such that it would be reasonably likely to adversely affect the collectability of any asset in any material respect;
	●	merging or consolidating with, or selling all or substantially all of its assets to, any third party;
	●	selling any collateral or creating or permitting to exist any adverse claim upon any collateral;
	●	engaging in any other business or activity than that contemplated by the Agreement;
	●	incurring or guaranteeing any debt for borrowed money;
	●	amending the Company’s certificate of incorporation or bylaws, making any loans or advances to, investments in, or paying any dividends to, any person unless both before and after any such loan, advance, investment or dividend there exists no actual event of default, potential event of default or termination event;
	●	removing an independent director on the board of directors except for cause or with the consent of the lender; or
	●	making payment on or issuing any subsidiary secured notes or debentures, or amending any agreements respecting such notes or debentures, if an event of default, potential event of default or termination event exists or would arise from any such action.
	In addition, the Company has agreed to maintain (i) a positive consolidated net income on a Non-GAAP basis (as defined and calculated under the Agreement) for each complete fiscal year and (ii) a tangible net worth on a Non-GAAP basis (again, as defined and calculated under the Agreement) of not less than $15 million, and (iii) maintain a borrowing base surplus or cash cushion sufficient to pay three to twelve months (increasing throughout 2013) of premiums and facility fees.
	Consolidated net income and tangible net worth as of and for the four quarters ended March 31, 2014, as calculated under the agreement, was $22,498,000 and $58,865,000 respectively.
	Advances under the Agreement are subject to a borrowing base formula, which limits the availability of advances on the borrowing base calculation based on attributes of policies pledged to the facility. Over-concentration of policies by insurance carrier, over-concentration of policies by insurance carriers with ratings below a AA- rating, and the premiums and facility fees reserve are the three primary factors with the potential of limiting availability of funds on the facility. Total funds available for additional borrowings under the borrowing base formula criteria at March 31, 2014 and December 31, 2013, were $4,740,000 and $3,937,000 respectively.
	On July 15, 2008, Holdings delivered a performance guaranty in favor of Autobahn pursuant to which it guaranteed the obligations of GWG Life, in its capacity as the seller and master servicer, under the Credit and Security Agreement and related documents. On January 29, 2013 and in connection with the Amended and Restated Credit and Security Agreement, Holdings delivered a reaffirmation of its performance guaranty. The obligations of Holdings under the performance guaranty and subsequent reaffirmation do not extend to the principal and interest owed by DLP II as the borrower under the credit facility.

Series_I_Secured_Notes_Payable

Series I Secured Notes Payable	3 Months Ended
	Mar. 31, 2014
Credit facilities and Series I Secured Notes Payable and Renewable Secured Debentures [Abstract]	'
Series I secured notes payable	'
	( 7 )       Series I Secured notes payable
	Series I Secured notes payable have been issued in conjunction with the GWG Series I Secured notes private placement memorandum dated August 25, 2009 (last revised November 15, 2010). On June 14, 2011 the Company closed the offering to additional investors, however, existing investors may elect to continue advancing amounts outstanding upon maturity subject to the Company’s option. Series I Secured notes have maturity dates ranging from six months to seven years with fixed interest rates varying from 5.65% to 9.55% depending on the term of the note. Interest is payable monthly, quarterly, annually or at maturity depending on the terms of the note. At March 31, 2014 and December 31, 2013 the weighted average interest rate of Series I Secured notes was 8.35%. The notes are secured by assets of GWG Life.  The principal amount outstanding under these Series I Secured notes was $29,224,000 and $29,744,000 at March 31, 2014 and December 31, 2013, respectively. The difference between the amount outstanding on the Series I Secured notes and the carrying amount on the consolidated balance sheet is due to netting of unamortized deferred issuance costs. Overall, interest expense includes amortization of deferred financing and issuance costs of $167,000 and $55,000 for the three-month periods ended March 31, 2014 and 2013, respectively. Future expected amortization of deferred financing costs is $622,000 over the next six years.
	On November 15, 2010, Jon Sabes and Steve Sabes pledged their ownership interests in the Company to the Series I Trust as security for advances under the Series I Trust arrangement.
	The use of proceeds from the issuances of Series I Secured notes was limited to the following: (1) payment of commissions of Series I Secured note sales, (2) purchase life insurance policies, (3) pay premiums of life insurance policies, (4) pay principal and interest to Senior Liquidity Provider (DZ Bank), (5) pay portfolio or note operating fees or costs, (6) pay trustee (Wells Fargo Bank, N.A.), (7) pay servicer and collateral fees, (8) pay principal and interest on Series I Secured notes, (9) make distributions to equity holders for tax liability related to portfolio, (10) purchase interest rate caps, swaps, or hedging instruments, (11) pay GWG Series I Trustee fees, and (12) pay offering expenses.
	On November 1, 2011, GWG entered into a Third Amended and Restated Note Issuance and Security Agreement with Lord Securities Corporation after receiving majority approval from the holders of Series I Secured notes. Among other things, the amended and restated agreement modified the use of proceeds and certain provisions relating to the distribution of collections and subordination of cash flow. Under the amended and restated agreement, GWG is no longer restricted as to its use of proceeds or subject to restrictions on certain distributions of collections and subordination of cash flows. Under the amended and restated agreement, GWG may extend the maturity of Series I Secured notes of a six month term for up to two additional six month terms, and Series I Secured notes of a one year term for up to six months.
	Future contractual maturities of Series I Secured notes payable at March 31, 2014 are as follows:
	Years Ending December 31,
	Nine months ending December 31 ,2014	$	8,323,000
	2015		8,638,000
	2016		7,193,000
	2017		4,252,000
	2018		754,000
	Thereafter		64,000
		$	29,224,000

Renewable_Secured_Debentures

Renewable Secured Debentures	3 Months Ended
	Mar. 31, 2014
Credit facilities and Series I Secured Notes Payable and Renewable Secured Debentures [Abstract]	'
Renewable Secured Debentures	'
	( 8 )       Renewable Secured Debentures
	The Company has registered with the Securities and Exchange Commission, effective January 2012, the offer and sale of $250,000,000 of secured debentures. Renewable Secured Debentures have maturity dates ranging from six months to seven years with fixed interest rates varying from 4.75% to 9.50% depending on the term of the note. Interest is payable monthly, annually or at maturity depending on the terms of the debenture. At March 31, 2014 and December 31, 2013, the weighted average interest rate of Renewable Secured Debentures was 7.53%. The debentures are secured by assets of GWG Life and GWG Holdings. The amount outstanding under these Renewable Secured Debentures was $149,065,000 and $134,891,000 at March 31, 2014 and December 31, 2013, respectively. The difference between the amount outstanding on the Renewable Secured Debentures and the carrying amount on the consolidated balance sheets is due to netting of unamortized deferred issuance costs and cash receipts for new issuances in process.  Amortization of deferred issuance costs was $847,000 and $278,000 for the three-month periods ended March 31, 2014 and 2013, respectively.  Future expected amortization of deferred financing costs as of March 31, 2014 is $5,418,000. Subsequent to March 31, 2014, the Company has issued approximately an additional $4,922,000 in principal amount of these Renewable Secured Debentures.
	The use of proceeds from the issuances of Renewable Secured Debentures is limited to the following: (1) payment of commissions on sales of Renewable Secured Debentures, (2) payment of offering expenses, (3) purchase of life insurance policies, (4) Payment of premiums on life insurance policies, (5) payment of principal and interest on Renewable Secured Debentures, (6) payment of portfolio operations expenses, and (7) for general working capital.
	Future contractual maturities of Renewable Secured Debentures at March 31, 2014 are as follows:
	Years Ending December 31,
	Nine months ending December 31, 2014	$	31,109,000
	2015		44,587,000
	2016		34,623,000
	2017		13,094,000
	2018		6,779,000
	Thereafter		18,873,000
		$	149,065,000
	The Company entered into an Indenture effective October 19, 2011 with Holdings as obligor, GWG Life as guarantor, and Bank of Utah as trustee for the benefit of the debenture holders.  The Indenture has certain financial and nonfinancial covenants.  The Company was in compliance with these covenants at March 31, 2014 and December 31, 2013.

Convertible_Redeemable_Preferr

Convertible, Redeemable Preferred Stock	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Convertible, redeemable preferred stock	'
	( 9 )     Convertible, redeemable preferred stock
	The Company began offering 3,333,333 shares of convertible redeemable preferred stock (Series A preferred stock) for sale to accredited investors in a private placement on July 31, 2011. The offering of Series A preferred stock concluded on September 2, 2012 and resulted in 3,278,000 shares being issued for gross consideration of $24,582,000. As of March 31, 2014, 193,000 shares have been issued as a result of conversion of $1,350,000 in dividends into shares of Series A preferred stock.  The Series A preferred stock was sold at an offering price of $7.50 per share. Series A preferred stock has a preferred yield of 10% per annum, and each share has the right to convert into 1.5 shares of the Company’s common stock. The Company may elect to automatically convert the Series A preferred stock to common stock as described below. Series A preferred shareholders also received three-year warrants to purchase, at an exercise price per share of $6.25, one share of common stock for every 20 shares of Series A preferred stock purchased.  The warrants are exercisable immediately. In the Certificate of Designations for the Series A preferred stock dated July 31, 2011, the Company has agreed to permit preferred shareholders to sell their shares back to the Company for the stated value of $7.50 per share, plus accrued dividends, according to the following schedule:
	●	Up to 33% of the holder’s unredeemed shares one year after issuance:
	●	Up to 66% of the holder’s unredeemed shares two years after issuance; and
	●	Up to 100% of the holder’s unredeemed shares three years after issuance.
	The Company’s obligation to redeem Series A preferred shares will terminate upon the Company completing a registration of its common stock with the SEC. The Company may redeem the Series A preferred shares at a price equal to 110% of their liquidation preference ($7.50 per share) at any time after December 15, 2012. As of March 31, 2014, the Company has not received any redemption requests.
	At the election of the Company, the Series A preferred shares may be automatically converted into the common stock of the Company in the event of either (1) a registered offering of the Company’s common stock with the SEC aggregating gross proceeds of at least $5.0 million at a price equal to or greater than $5.50 per share of common stock, or (2) the consent of shareholders holding at least a majority of the then-outstanding shares of Series A preferred stock. As of March 31, 2014, the Company had issued 3,395,000 preferred shares resulting in gross consideration of $25,364,000 (including cash proceeds, conversion of Series I Secured notes and accrued interest on Series I notes, and conversion of preferred dividends payable).  The Company incurred Series A preferred stock issuance costs of $2,838,000, of which $2,510,000 was amortized to additional paid in capital through March 31, 2014, resulting in a carrying amount of $25,036,000.
	The Company determined that the grant date fair value of the outstanding warrants attached to the Series A preferred stock was $395,000 for warrants outstanding as of  March 31, 2014. The Company may redeem outstanding warrants prior to their expiration, at a price of $0.01 per share upon 30 days written notice to the investors at any time after (i) the Company has completed a registration of its common stock with the SEC and (ii) the volume of weighted average sale price per share of common stock equals or exceeds $7.00 per share for ten consecutive trading days ending on the third business day prior to proper notice of such redemption. Total warrants outstanding as of March 31, 2014, were 831,909 with a weighted average remaining life of 1.10 years. Total warrants outstanding at December 31, 2013, were 831,909 with a weighted average remaining life of 1.34 years. As of March 31, 2014 none of these warrants have been exercised.
	Dividends on the Series A preferred stock may be paid in either cash or additional shares of Series A preferred stock at the election of the holder and approval of the Company. The dividends are reported as an expense and included in the caption interest expense in the consolidated statements of operations. The Company declared and accrued dividends of $634,000 and $635,000 during the three months ended March 31, 2014 and 2013, respectively, pursuant to a board resolution declaring the dividend.  27,000 and 12,000 shares of Series A preferred stock were issued in lieu of cash dividends in the three-month periods ended March 31, 2014 and 2013, respectively. The shares issued in lieu of cash dividends were issued at $7.00 per share.  As of March 31, 2014, Holdings has $634,000 of accrued preferred dividends which were paid or converted to shares of Series A preferred stock on April 15, 2014.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income taxes [Abstract]	'
Income taxes	'
	(10)       Income taxes
	The Company did not have any current income taxes for the three months ended March 31, 2014, and had current income taxes of $2,000 for the three months ended March 31, 2013.  For the three months ended March 31, 2014, the Company recognized income tax benefit of $955,000, or 33.4% of income before taxes, compared to the recognition of an income tax expense of $566,000, or 89.4% for the three months ended March 31, 2013. The primary differences between the Company’s March 31, 2014 effective tax rate and the statutory federal rate are the accrual of non-deductible preferred stock dividend expense of $635,000, state taxes, and other non-deductible expenses.
	The most significant temporary differences between GAAP net income and taxable net income are the treatment of interest costs with respect to the acquisition of the life insurance policies and revenue recognition with respect to the mark-to-market of life insurance portfolio.

Common_Stock

Common Stock	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Common Stock	'
	(11)           Common Stock
	On July 11, 2011, we entered into a Purchase and Sale Agreement with Athena Securities Group, Ltd. and Athena Structured Funds PLC. Under this agreement, we issued to Athena Securities Group, Ltd. (Athena) 989,000 shares of common stock, which was equal to 9.9% of our outstanding shares, in exchange for shares equal to 9.9% of the outstanding shares in Athena Structured Funds, PLC and cash of $5,000. This 2011 agreement had contemplated cooperative efforts by the parties aimed at developing a security and related offering in Europe or Ireland, the proceeds of which would be used to finance the acquisition of life-insurance related assets in the United States. In 2013, we sought to terminate the 2011 agreement due to a changing regulatory environment in Europe that negatively affected the likelihood of consummating the contemplated offering of securities, and our dissatisfaction with Athena’s performance under the 2011 agreement. As a result, in June 2013 we entered into a second Purchase and Sale Agreement with Athena Securities Ltd. and Athena. This agreement effected the termination of the 2011 agreement. The June 2013 agreement contained mutual general releases of claims and substantially unwound certain capital stock transactions that had been effected under the 2011 agreement. In particular, Athena returned to us for redemption 865,000 shares of our common stock, and retained 124,000 common shares in recognition of their earlier efforts under the 2011 agreement. For our part, we sold back to Athena all of our ownership in Athena Structured Funds, PLC that we had originally acquired under the 2011 agreement. Presently, we have no ongoing business relationship with Athena.

Stock_Incentive_Plan

Stock Incentive Plan	3 Months Ended
	Mar. 31, 2014
Stock Incentive Plan [Abstract]	'
Stock Incentive Plan	'
	(12)           Stock Incentive Plan
	The Company adopted the GWG Holdings, Inc. 2013 Stock Incentive Plan on March 27, 2013. The plan shall be administered by Compensation Committee of the Board of Directors of the Company. The Company’s Chief Executive Officer may, on a discretionary basis and without committee review or approval, grant incentives to new employees of the Company who are not Officers of the Company. Incentives under the plan may be granted in one or a combination of the following forms: (a) incentive stock options and non-statutory stock options; (b) stock appreciation rights; (c) stock awards; (d) restricted stock; (e) restricted stock units; and (f) performance shares.  Eligible participants include officers and employees of the company, members of the Board of Directors, and consultants or other independent contractors. 2,000,000 shares are issuable under the plan. No person shall receive grants of stock options and SARs under the plan that exceed, in the aggregate 400,000 shares of common stock in any one year. The term of each stock option shall be determined by the committee but shall not exceed ten years. Vested stock options may be exercised in whole or part by the holder giving notice to the Company. The holder of the option may provide payment for the exercise price or surrender shares equal to the exercise price.
	The Company issued stock options for 855,000 shares of common stock to employees, officers, and directors of the Company in 2013. Options for 403,000 shares vested immediately, and the remaining options vested over three years. The shares were issued with an exercise price of $4.14 for those owning more than 10% of the Company’s stock and of $3.76 for others, which is equal to the estimated market price of the shares on the date of grant valued using Black-Scholes Binomial option pricing model. The expected volatility used in the Black-Scholes model valuation of options issued during the year was 19.73% annualized. The annual volatility rate is based on the standard deviation of the average continuously compounded rate of return of five selected comparable companies over the previous 52 weeks. Forfeiture rate of 15% is based on historical company information and expected future trend. As of March 31, 2014 stock options for 108,500 shares were forfeited.
	Stock options granted through March 31, 2014:
		Exercise								Binomial		Forfeiture		Compensation
	Grant Date	Price			Shares			Vesting		Value		Factor		Expense
	9/5/13	$	3.76			285,000		Immediate			0.18		0.87	$	44,631
	9/5/13	$	4.14			50,000		Immediate			0.18		0.87	$	7,830
	9/5/13	$	3.76			88,677		1 year			0.18		0.85	$	13,568
	9/5/13	$	4.14			5,667		1 year			0.18		0.85	$	867
	9/5/13	$	3.76			88,666		2 years			0.3		0.7225	$	19,218
	9/5/13	$	4.14			5,667		2 years			0.3		0.7225	$	1,228
	9/5/13	$	3.76			88,657		3 years			0.41		0.6141	$	22,323
	9/5/13	$	4.14			5,666		3 years			0.41		0.6141	$	1,427
	9/30/13	$	3.76			8,000		Immediate			0.33		0.87	$	2,297
	10/28/13	$	3.76			14,000		1 year			0.33		0.85	$	3,927
	10/28/13	$	3.76			14,000		2 years			0.46		0.7225	$	4,653
	10/28/13	$	3.76			14,000		3 years			0.57		0.6141	$	4,901
	11/18/13	$	3.76			8,334		1 year			0.33		0.85	$	2,338
	11/18/13	$	3.76			8,333		2 years			0.46		0.7225	$	2,769
	11/18/13	$	3.76			8,333		3 years			0.57		0.6141	$	2,917
	12/12/13	$	3.76			60,000		Immediate			0.33		0.87	$	17,226
	12/12/13	$	3.76			34,000		1 year			0.33		0.85	$	9,537
	12/12/13	$	3.76			34,000		2 years			0.46		0.7225	$	11,300
	12/12/13	$	3.76			34,000		3 years			0.57		0.6141	$	11,901
						855,000
	Outstanding stock options:
		Vested			Un-vested				Total
	Balance as of December 31, 2013		375,500			423,500				799,000
	Granted during the year		-			-				-
	Exercised during the year		-			-				-
	Forfeited during the year		(20,000	)		(32,500	)			(52,500	)
	Expired during the year		-			-				-
	Balance as of March 31, 2014		355,500			391,000				746,500
	Compensation expense related to un-vested options not yet recognized is $105,315.  We expect to recognize this compensation expense over the next 2.75 years. Stock-based compensation cost for the three months ended March 31, 2014 was $56,000.

Net_loss_per_common_share

Net loss per common share	3 Months Ended
	Mar. 31, 2014
Net loss per common share [Abstract]	'
Net loss per common share	'
	( 13 )     Net loss per common share
	The Company began issuing Series A preferred stock September, 1, 2011, as described in note 9. The Series A preferred stock is anti-dilutive to the net loss per common share calculation at March 31, 2014 and 2013. The Company has also issued warrants to purchase common stock in conjunction with the sale of convertible preferred stock, as discussed in note 9. The warrants are anti-dilutive at March 31, 2014 and 2013, and have not been included in the fully diluted net loss per common share calculation.

Commitments

Commitments	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies [Abstract]	'
Commitments	'
	( 14 )     Commitments
	The Company entered into an office lease with U.S. Bank National Association as the landlord. The lease was effective April 22, 2012 with a term through August 31, 2015. The lease is for 11,695 square feet of office space located at 220 South Sixth Street, Minneapolis, Minnesota. The Company is obligated to pay base rent plus common area maintenance and a share of the building operating costs. Rent expenses under this agreement were $52,000 and $48,000 for the three months ended March 31, 2014 and 2013, respectively. Minimum lease payments under the lease agreement effective April 22, 2012 are as follows:
	Nine months ending December 31, 2014		78,000
	2015		70,000
	Total	$	148,000

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies [Abstract]	'
Contingencies	'
	( 15 )    Contingencies
	Litigation - In the normal course of business, the Company is involved in various legal proceedings. In the opinion of management, any liability resulting from such proceedings would not have a material adverse effect on the Company’s financial position, results of operations or cash flows.
	Opportunity Finance, LLC, owned by Jon Sabes and Steven Sabes, is subject to litigation clawback claims by the bankruptcy trustee for third-party matters for payments that may have been deemed preference payments. In addition, Jon Sabes and Steven Sabes are subject to litigation clawback claims by the bankruptcy trustee for third-party matters for payments received from Opportunity Finance that may have been deemed preference payments. If the parties are unsuccessful in defending against these claims, their equity ownership in the Company may be sold or transferred to other parties to satisfy such claims. In addition, the Company loaned $1,000,000 to Opportunity Finance, LLC, and was repaid in full plus interest of $177,000. This investment amount may also be subject to clawback claims by the bankruptcy court.

Guarantees_of_Secured_Debentur

Guarantees of Secured Debentures	3 Months Ended
	Mar. 31, 2014
Guarantees of Secured Debentures [Abstract]	'
Guarantees of secured debentures	'
	( 16 )    Guarantees of secured debentures
	Holdings has registered with the SEC the offer and sale $250,000,000 of secured debentures as described in note 8. The secured debentures are secured by the assets of Holdings as described in note 8 and a pledge of all the common stock by the largest shareholders. Obligations under the debentures are guaranteed by GWG Life. This guarantee involves the grant of a security interest in all the assets of GWG Life. The payment of principal and interest on the secured debentures is fully and unconditionally guaranteed by GWG Life. Substantially all of the Company’s life insurance policies are held by DLP II and the Trust. The policies held by DLP II are not collateral for the debenture obligations as such policies are collateral for the credit facility.
	The consolidating financial statements are presented in lieu of separate financial statements and other related disclosures of the subsidiary guarantors and issuer because management does not believe that separate financial statements and related disclosures would be material to investors. There are currently no significant restrictions on the ability of Holdings or GWG Life, the guarantor subsidiary, to obtain funds from its subsidiaries by dividend or loan, except as follows. DLP II is a borrower under a credit agreement with Autobahn, with DZ Bank AG as agent, as described in note 6. The significant majority of insurance policies owned by the Company are subject to a collateral arrangement with DZ Bank AG described in note 6. Under this arrangement, collection and escrow accounts are used to fund premiums of the insurance policies and to pay interest and other charges under the revolving credit facility. DZ Bank AG and Autobahn must authorize all disbursements from these accounts, including any distributions to GWG Life. Distributions are limited to an amount that would result in the borrowers (DLP II, GWG Life and Holdings) realizing an annualized rate of return on the equity funded amount for such assets of not more than 18%, as determined by DZ Bank AG. After such amount is reached, the credit agreement requires that excess funds be used for repayments of borrowings before any additional distributions may be made.
	The following represents consolidating financial information as of March 31, 2014 and December 31, 2013, with respect to the financial position, and for the three months ended March 31, 2014 and 2013 with respect to results of operations and cash flows of Holdings and its subsidiaries. The parent column presents the financial information of Holdings, the primary obligor of the secured debentures. The guarantor subsidiary column presents the financial information of GWG Life, the guarantor subsidiary of the secured debentures, presenting its investment in DLP II and Trust under the equity method. The non-guarantor subsidiaries column presents the financial information of all non-guarantor subsidiaries including DLP II and Trust.
	Condensed Consolidating Balance Sheets
		Parent				Guarantor Sub			Non-Guarantor Sub			Eliminations				Consolidated
	31-Mar-14
	A S S E T S
	Cash and cash equivalents		$	26,466,468			$	1,616,831		$	-		$	-			$	28,083,299
	Restricted cash			-				350,000			2,503,763			-				2,853,763
	Investment in life settlements, at fair value			-				-			254,503,535			-				254,503,535
	Other assets			395,201				723,040			1,018,425			-				2,136,666
	Investment in subsidiaries			148,405,194				177,845,326			-			(326,250,520	)			-
	TOTAL ASSETS		$	175,266,863			$	180,535,197		$	258,025,723		$	(326,250,520	)		$	287,577,263
	L I A B I L I T I E S & S T O C K H O L D E R S’ E Q U I T Y (D E F I C I T)
	LIABILITIES
	Revolving credit facility		$	-			$	-		$	79,000,000		$	-			$	79,000,000
	Series I Secured notes payable			-				28,602,238			-			-				28,602,238
	Renewable Secured Debentures			145,989,431				-			-			-				145,989,431
	Interest payable			4,584,861				3,143,600			670,731			-				8,399,192
	Accounts payable and other accrued expenses			399,308				384,165			509,666			-				1,293,139
	Deferred taxes			6,720,316				-			-			-				6,720,316
	TOTAL LIABILITIES			157,693,916				32,130,003			80,180,397			-				270,004,316
	CONVERTIBLE, REDEEMABLE PREFERRED STOCK			25,036,056				-			-			-				25,036,056
	STOCKHOLDERS’ EQUITY (DEFICIT)
	Member capital			-				148,405,194			177,845,326			(326,250,520	)			-
	Common stock			9,124				-			-			-				9,124
	Additional paid-in capital			2,867,514				-			-			-				2,867,514
	Accumulated deficit			(10,339,747	)			-			-			-				(10,339,747	)
	TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)			(7,463,109	)			148,405,194			177,845,326			(326,250,520	)			(7,463,109	)
	TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		$	175,266,863			$	180,535,197		$	258,025,723		$	(326,250,520	)		$	287,577,263
	Condensed Consolidating Balance Sheets (continued)
		Parent				Guarantor Subsidiary			Non-Guarantor Subsidiaries			Eliminations				Consolidated
	31-Dec-13
	A S S E T S
	Cash and cash equivalents	$	32,711,636			$	738,157		$	-		$	-			$	33,449,793
	Restricted cash		-				1,420,000			4,412,970			-				5,832,970
	Investment in life settlements, at fair value		-				-			234,672,794			-				234,672,794
	Other assets		381,883				484,510			558,526			-				1,424,919
	Investment in subsidiaries		129,839,241				159,798,490			-			(289,637,731	)			-
	TOTAL ASSETS	$	162,932,760			$	162,441,157		$	239,644,290		$	(289,637,731	)		$	275,380,476
	L I A B I L I T I E S  &  S T O C K H O L D E R S'  E Q U I T Y  (D E F I C I T)
	LIABILITIES
	Revolving credit facility	$	-			$	-		$	79,000,000		$	-			$	79,000,000
	Series I Secured notes payable		-				29,275,202			-			-				29,275,202
	Renewable Secured Debentures		131,646,062				-			-			-				131,646,062
	Interest payable		3,806,820				3,065,465			337,123			-				7,209,408
	Accounts payable and other accrued expenses		574,026				261,249			508,667			-				1,343,952
	Deferred taxes		7,675,174				-			-			-				7,675,174
	TOTAL LIABILITIES		143,702,082				32,601,916			79,845,800			-				256,149,798
	CONVERTIBLE, REDEEMABLE PREFERRED STOCK		24,722,693				-			-			-				24,722,693
	STOCKHOLDERS’ EQUITY (DEFICIT)
	Member capital		-				129,839,241			159,798,490			(289,637,731	)			-
	Common stock		9,124				-			-			-				9,124
	Additional paid-in capital		2,937,438				-			-			-				2,937,438
	Accumulated deficit		(8,438,577	)			-			-			-				(8,438,577	)
	TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)		(5,492,015	)			129,839,241			159,798,490			(289,637,731	)			(5,492,015	)
	TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$	162,932,760			$	162,441,157		$	239,644,290		$	(289,637,731	)		$	275,380,476
	Condensed Consolidating Statements of Operations
	For the three months ended March 31, 2014	Parent				Guarantor			Non-Guarantor			Eliminations				Consolidated
						Subsidiary			Subsidiaries
	REVENUE
	Contract servicing fees	$	-			$	966,056		$	-		$	(966,056	)		$	-
Gain on life settlements, net		-				-			5,516,205			-				5,516,205
Interest and other income		6,929				169,615			44			(169,221	)			7,367
TOTAL REVENUE		6,929				1,135,671			5,516,249			(1,135,277	)			5,523,572
EXPENSES
Origination and servicing fees		-				-			966,056			(966,056	)			-
Employee compensation and benefits		590,584				378,162			-			-				968,746
Legal and professional fees		266,159				59,139			-			-				325,298
Interest expense		4,216,528				778,567			1,331,453			-				6,326,548
Other expenses		421,243				325,255			181,731			(169,221	)			759,008
TOTAL EXPENSES		5,494,514				1,541,123			2,479,240			(1,135,277	)			8,379,600
INCOME (LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES		(5,487,585	)			(405,452	)		3,037,009			-				(2,856,028	)
EQUITY IN INCOME OF SUBSIDIARY		2,631,557				3,037,009			-			(5,668,566	)			-
NET INCOME (LOSS) BEFORE INCOME TAXES		(2,856,028	)			2,631,557			3,037,009			(5,668,566	)			(2,856,028	)
INCOME TAX BENEFIT		(954,858	)			-			-			-				(954,858	)
NET INCOME (LOSS)	$	(1,901,170	)		$	2,631,557		$	3,037,009		$	(5,668,566	)		$	(1,901,170	)
For the three months ended March 31, 2013	Parent				Guarantor			Non-Guarantor			Eliminations				Consolidated
					Subsidiary			Subsidiaries
REVENUE
Contract servicing fees	$	-			$	1,278,102		$	-		$	(1,278,102	)		$	-
Gain on life settlements, net		-				-			8,340,356			-				8,340,356
Interest and other income		8,091				136,569			23,010			-				167,670
TOTAL REVENUE		8,091				1,414,671			8,363,366							8,508,026
EXPENSES
Origination and servicing fees		-				-			1,278,102			(1,278,102	)			-
Employee compensation and benefits		1,546,702				390,718			-			-				1,937,420
Legal and professional fees		399,523				37,767			-			-				437,290
Interest expense		2,321,169				907,175			1,238,871			-				4,467,215
Other expenses		634,155				386,490			12,499			-				1,033,144
TOTAL EXPENSES		4,901,549				1,722,150			2,529,472			(1,278,102	)			7,875,069
INCOME (LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES		(4,893,458	)			(307,479	)		5,883,894			-				632,957
EQUITY IN INCOME OF SUBSIDIARY		5,526,115				5,882,414			-			(11,408,529	)			-
NET INCOME BEFORE INCOME TAXES		632,657				5,574,935			5,833,894			(11,408,529	)			632,957
INCOME TAX EXPENSE		565,523				300			-			-				565,823
NET INCOME	$	67,134			$	5,574,635		$	5,833,894		$	(11,408,529	)		$	67,134
Condensed Consolidating Statements of Cash Flows
For the three months ended March 31, 2014	Parent				Guarantor Sub			Non-Guarantor Sub			Eliminations				Consolidated
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$	(1,901,170	)		$	2,631,557		$	3,037,009		$	(5,668,566	)		$	(1,901,170	)
Adjustments to reconcile net loss to cash:
(Equity) loss of subsidiaries		(2,631,557	)			(3,037,009	)		-			5,668,566				-
Life settlements – change in fair value		-				-			(11,358,913	)		-				(11,358,913	)
Amortization of deferred financing and issuance costs		847,236				166,946			(660,525	)		-				353,657
Deferred income taxes		(954,858	)			-			-			-				(954,858	)
Preferred stock issued for dividends		192,340				-			-			-				192,340
(Increase) in operating assets:
Other assets		(15,947,713	)			(15,248,357	)		-			30,944,224				(251,846	)
Increase in operating liabilities:
Accounts payable and other accrued expenses		713,785				229,443			334,598			-				1,277,826
NET CASH FLOWS USED IN OPERATING ACTIVITIES		(19,681,937	)			(15,257,420	)		(8,647,831	)		30,944,224				(12,642,964	)
CASH FLOWS FROM INVESTING ACTIVITIES
Investment in life settlements		-				-			(8,271,203	)		-				(8,271,203	)
NET CASH FLOWS USED IN INVESTING ACTIVITIES		-				-			(8,271,203	)		-				(8,271,203	)
CASH FLOWS FROM FINANCING ACTIVITIES
Payments for redemption of Series I Secured notes payable		-				(868,303	)		-			-				(868,303	)
Proceeds from issuance of debentures		18,365,657				-			-			-				18,365,657
Payments for issuance costs and redemption of Renewable Secured Debentures		(4,928,888	)			-			-			-				(4,928,888	)
Proceeds from restricted cash		-				1,070,000			1,909,207			-				2,979,207
Issuance of member capital		-				15,934,397			15,009,827			(30,944,224	)			-
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		13,436,769				16,136,094			16,919,034			(30,944,224	)			15,547,673
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(6,245,168	)			878,674			-			-				(5,366,494	)
CASH AND CASH EQUIVALENTS
BEGINNING OF THE PERIOD		32,711,636				738,157			-			-				33,449,793
END OF THE PERIOD	$	26,466,468			$	1,616,831		$	-		$	-			$	28,083,299
Consolidating Statements of Cash Flows (continued)
For the three months ended March 31, 2013	Parent				Guarantor Sub			Non-Guarantor Sub			Eliminations				Consolidated
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$	67,134			$	5,574,635		$	5,833,894		$	(11,408,529	)		$	67,134
Adjustments to reconcile net loss to cash:
(Equity) loss of subsidiaries		(5,526,115	)			(5,882,414	)		-			11,408,529				-
Life settlements – change in fair value		-				-			(11,494,725	)		-				(11,494,725	)
Amortization of deferred financing and issuance costs		393,477				272,505			427,765			-				1,093,747
Deferred income taxes		563,874				-			-			-				563,874
Preferred stock issued for dividends		83,702				-			-			-				83,702
(Increase) decrease in operating assets:
Other assets		(14,274,237	)			(10,700,326	)		669,198			24,856,539				551,174
Increase in operating liabilities:
Accounts payable and other accrued expenses		844,042				131,527			315,187			-				1,290,756
NET CASH FLOWS USED IN OPERATING ACTIVITIES		(17,848,123	)			(10,604,073	)		(4,248,681	)		24,856,539				(7,844,338	)
CASH FLOWS FROM INVESTING ACTIVITIES
Investment in life settlements		-				-			(9,913,049	)		-				(9,913,049	)
Proceeds from settlement of life settlements		-				-			1,490,000			-				1,490,000
NET CASH FLOWS USED IN INVESTING ACTIVITIES		-				-			(8,423,049	)		-				(8,423,049	)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from revolving credit facility		-				-			8,000,000			-				8,000,000
Payments for redemption of Series I Secured notes payable		-				(1,507,824	)		-			-				(1,507,824	)
Proceeds from issuance of debentures		23,850,794				-			-			-				23,850,794
Payments for issuance costs and redemption of Renewable Secured Debentures		(2,303,268	)			-			-			-				(2,303,268	)
Proceeds (payments) from restricted cash		-				1,469,676			(6,000,784	)		-				(4,531,108	)
Payments for redemption of preferred stock		(186,669	)													(186,669	)
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		21,360,857				14,145,877			12,671,730			(24,856,539	)			23,321,925
NET INCREASE IN CASH AND CASH EQUIVALENTS		3,512,734				3,541,804			-			-				7,054,538
CASH AND CASH EQUIVALENTS
BEGINNING OF THE PERIOD		25,035,579				2,461,465			-			-				27,497,044
END OF THE PERIOD	$	28,548,313			$	6,003,269		$	-		$	-			$	34,551,582

Concentrations

Concentrations	3 Months Ended
	Mar. 31, 2014
Concentrations [Abstract]	'
Concentration	'
	17 )     Concentrations
	GWG purchases life insurance policies written by life insurance companies having investment grade ratings by independent rating agencies.  As a result there may be certain concentrations of contracts with life insurance companies.  The following summarizes the face value of insurance contracts with specific life insurance companies exceeding 10% of the total face value held by the Company.
		March 31,		December 31,
		2014		2013
	Life insurance company	%		%
	Company A		15.98		16.58
	Company B		11.13		11.34
	The following summarizes the number of insurance contracts held in specific states exceeding 10% of the total face value held by the Company:
		March 31,		December 31,
		2014		2013
	State of residence	%		%
	California		27.97		28.14
	Florida		15.38		15.59
	New York		10.84		10.65

Nature_of_Business_and_Summary1

Nature of Business and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Nature of Business and Summary of Significant Accounting Policies [Abstract]	'
Nature of business	'
	Nature of business - GWG Holdings, Inc. and subsidiaries, located in Minneapolis, Minnesota, facilitates the purchase of life insurance policies for its own investment portfolio through its wholly owned subsidiary, GWG Life Settlements, LLC (GWG Life), and its subsidiaries, GWG Trust (Trust), GWG DLP Funding II, LLC (DLP II) and its wholly owned subsidiary, GWG DLP Master Trust II (the Trust II). Our wholly owned subsidiary, GWG Broker Services, LLC (Broker Services), was formed to earn fees for brokering policy transactions between market participants. Our wholly owned subsidiary United Lending, LLC (United Lending) and its wholly owned subsidiary United Lending SPV, LLC (United Lending SPV) were formed to finance life settlement premiums and policy loans.  All of these entities are legally organized in Delaware. Unless the context otherwise requires or we specifically so indicate, all references in this report to "we", "us", "our", "our Company", "GWG", or the "Company" refer to these entities collectively. GWG Member, LLC, a wholly owned subsidiary formed November 2010 to facilitate the acquisition of policies, has not commenced operations as of December 31, 2013. The entities were legally organized in Delaware and are collectively referred herein to as GWG, or the Company.
Basis of presentation	'
	Basis of presentation - The condensed consolidated balance sheet as of March 31, 2014, the condensed consolidated statements of operations for the three months ended March 31, 2014 and 2013, and the condensed consolidated statements of cash flows for the three months ended March 31, 2014 and 2013, and the related information presented in these notes, have been prepared by management in accordance with U.S. generally accepted accounting principles (“GAAP”)  for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X, without audit. To the extent that information and notes required by U.S. generally accepted accounting principles for complete financial statements are contained in or are consistent with the consolidated audited financial statements in the Company’s Form 10-K for the year ended December 31, 2013, such information and notes have not been duplicated herein . In the opinion of management, all adjustments considered necessary for a fair presentation of results have been included. The condensed consolidated balance sheet at December 31, 2013 was derived from the audited consolidated financial statements as of that date. Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Special Financial Report on Form 10-K for the year ended December 31, 2013.
Use of estimates	'
	Use of estimates - The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making
	judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. The most significant estimates with regard to these consolidated financial statements relates to (1) the determination of the assumptions used in estimating the fair value of the investment in life insurance policies, and (2) the value of deferred tax assets and liabilities.
Life settlements	'
	Life settlements - ASC 325-30, Investments in Insurance Contracts, allows a reporting entity the election to account for its investments in life settlements using either the investment method or the fair value method. The election shall be made on an instrument-by-instrument basis and is irrevocable. Under the investment method, an investor shall recognize the initial investment at the purchase price plus all initial direct costs. Continuing costs (policy premiums and direct external costs, if any) to keep the policy in force shall be capitalized. Under the fair value method, an investor shall recognize the initial investment at the purchase price. In subsequent periods, the investor shall remeasure the investment at fair value in its entirety at each reporting period and shall recognize the change in fair value in current period income net of premiums paid. The Company uses the fair value method to account for all life settlements.
	The Company recognizes realized gains (revenue) from life settlement contracts upon one of the two following events:
		1)	Receipt of death notice or verified obituary of insured
		2)	Sale of policy and filing of change of ownership forms and receipt of payment
	The Company recognizes the difference between the death benefits and carrying values of the policy when an insured event has occurred and the Company determines that settlement and ultimate collection of the death benefits is realizable and reasonably assured. Revenue from a transaction must meet both criteria in order to be recognized. In an event of a sale of a policy the Company recognizes gain or loss as the difference between the sale price and the carrying value of the policy on the date of the receipt of payment on such sale.
	Deposits and initial direct costs advanced on unsettled policy acquisitions are recorded as other assets until policy ownership has been transferred to the Company.  Such deposits and direct cost advances were $0 and $201,000 at March 31, 2014 and December 31, 2013, respectively.
Deferred financing and issuance costs	'
	Deferred financing and issuance costs – Costs incurred to obtain financing under the revolving credit facility, as described in note 6, have been capitalized and are amortized using the straight-line method over the term of the revolving credit facility. Amortization of deferred financing costs was $89,000 and $187,000 for the three month periods ended March 31, 2014 and 2013, respectively. The future amortization is expected to be $268,000 for the nine months ending December 31, 2014.  The Series I Secured notes payable, as described in note 7, are reported net of issuance costs, sales commissions and other direct expenses, which are amortized using the interest method over the term of each respective borrowing. The Renewable Secured debentures, as described in note 8, are reported net of issuance costs, sales commissions and other direct expenses, which are amortized using the interest method over the term of each respective borrowing. The Series A preferred stock, as described in note 9, is reported net of issuance costs, sales commissions, including the fair value of warrants issued, and other direct expenses, which are amortized using the interest method as interest expense over the three-year redemption period.
Earnings (loss) per share	'
	Earnings (loss) per share - Basic per share earnings (loss) attributable to non-redeemable interests is calculated using the weighted-average number of shares outstanding during the period. Diluted earnings per share is calculated based on the potential dilutive impact, if any, of the Company’s convertible, redeemable preferred stock, and outstanding warrants, and stock options.
Subsequent events	'
	Subsequent events - Subsequent events are events or transactions that occur after the balance sheet date but before consolidated financial statements are issued. The Company recognizes in the consolidated financial statements the effects of all subsequent events that provide additional evidence about conditions that existed at the date of the balance sheet, including the estimates inherent in the process of preparing the consolidated financial statements. The Company’s consolidated financial statements do not recognize subsequent events that provide evidence about conditions that did not exist at the date of the balance sheet but arose after the balance sheet date and before the consolidated financial statements are available to be issued. The Company evaluates subsequent events and transactions that occur after the balance sheet date up to the date that the consolidated financial statements are filed for potential recognition or disclosure.
Recently adopted pronouncements	'
	Recently adopted pronouncements - Pronouncements issued by the FASB or other authoritative accounting standards groups with future effective dates are either not applicable or are not expected to be significant to the Company.

Investment_in_Life_Insurance_P1

Investment in Life Insurance Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Investment in Life Insurance Policies [Abstract]	'
Summary of life insurance policies, under the fair value method and estimated maturity dates, based on remaining life expectancy	'
		As of March 31, 2014								As of December 31, 2013
	Years Ending December 31,	Number of Contracts			Estimated Fair Value			Face Value		Number of Contracts		Estimated Fair Value		Face Value
	2014		-		$	-		$	-		-	$	-	$	-
	2015		4			5,238,000			6,750,000		4		5,065,000		6,750,000
	2016		11			10,610,000			16,800,000		8		8,174,000		13,750,000
	2017		29			32,186,000			59,916,000		25		33,345,000		63,916,000
	2018		30			34,573,000			71,017,000		33		37,243,000		80,318,000
	2019		41			43,654,000			113,795,000		34		32,844,000		89,295,000
	2020		37			30,497,000			81,014,000		34		27,741,000		75,644,000
	Thereafter		134			97,746,000			422,648,000		125		90,261,000		410,975,000
	Totals		286			254,504,000			771,940,000		263	$	234,673,000	$	740,648,000
Reconciliation of gain on life settlements	'
	Three Months Ended:	March 31,			March 31,
		2014			2013
	Change in fair value	$	11,359,000		$	11,495,000
	Premiums and other annual fees		(5,843,000	)		(5,665,000	)
	Policy maturities		-			2,510,000
	Gain on life settlements, net	$	5,516,000		$	8,340,000
Estimated expected premium payments to maintain the above life insurance policies assuming no mortalities	'
	Years Ending December 31,
	Nine months ending December 31 ,2014	$	17,882,000
	2015		26,078,000
	2016		28,550,000
	2017		32,109,000
	2018		35,155,000
		$	139,774,000

Fair_Value_Definition_and_Hier1

Fair Value Definition and Hierarchy (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Definition and Hierarchy [Abstract]	'
Reconciliation of investments in life insurance policies	'
			2014				2013
	Beginning balance	$	234,673,000			$	164,317,000
	Purchases		8,472,000				10,698,000
	Maturities (acquisition cost basis)		-				(1,490,000	)
	Gross unrealized gains		11,359,000				11,616,000
	Gross unrealized losses		-				(121,000	)
	Ending balance	$	254,504,000			$	185,020,000
Summary of inputs utilized in estimating the fair value	'
	As of			As of
	March 31,			December 31,
	2014			2013
	Weighted average age of insured		82.3				82.1
	Weighted average life expectancy, months*		84.3				87
	Average face amount per policy	$	2,699,000			$	2,816,000
	Discount rate		11.69	%			11.69	%
	* Standard life expectancy as adjusted for insured’s specific circumstances.
Fair value sensitivity analysis on the investment in life insurance policies	'
		Changes in fair value of life insurance policies
	Change in life expectancy estimates	plus 8				minus			plus				minus
		months				8 months			4 months				4 months
	31-Mar-14		$	(36,833,000	)		$	38,756,000		$	(18,658,000	)		$	19,145,000
	31-Dec-13		$	(34,382,000	)		$	36,152,000		$	(17,417,000	)		$	17,865,000
	Change in discount rate	plus 2%					minus 2%			plus 1%				minus 1%
	31-Mar-14		$	(23,949,000	)		$	28,161,000		$	(12,446,000	)		$	13,496,000
	31-Dec-13		$	(22,944,000	)		$	27,063,000		$	(11,933,000	)		$	12,959,000
Warrants Level 3 instruments and measured at fair value upon issuance	'
	As of March 31, 2014:
	Month issued	Warrants				Fair value			Risk				Volatility			Term
		issued				per share			free rate
	Dec-11		137,874			$	0.11			0.42	%			25.25	%	3 years
	Mar-12		76,260			$	0.26			0.38	%			36.2	%	3 years
	Jun-12		323,681			$	0.58			0.41	%			47.36	%	3 years
	Jul-12		289,093			$	0.58			0.41	%			47.36	%	3 years
	Sep-12		5,000			$	0.36			0.31	%			40.49	%	3 years
			831,908

Series_I_Secured_Notes_Payable1

Series I Secured Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2014
Credit facilities and Series I Secured Notes Payable and Renewable Secured Debentures [Abstract]	'
Future contractual maturities of series I secured notes payable	'
	Years Ending December 31,
	Nine months ending December 31 ,2014	$	8,323,000
	2015		8,638,000
	2016		7,193,000
	2017		4,252,000
	2018		754,000
	Thereafter		64,000
		$	29,224,000

Renewable_Secured_Debentures_T

Renewable Secured Debentures (Tables)	3 Months Ended
	Mar. 31, 2014
Credit facilities and Series I Secured Notes Payable and Renewable Secured Debentures [Abstract]	'
Summary of Future maturities of renewable secured debentures	'
	Years Ending December 31,
	Nine months ending December 31, 2014	$	31,109,000
	2015		44,587,000
	2016		34,623,000
	2017		13,094,000
	2018		6,779,000
	Thereafter		18,873,000
		$	149,065,000

Stock_Incentive_Plan_Tables

Stock Incentive Plan (Tables)	3 Months Ended
	Mar. 31, 2014
Stock Incentive Plan [Abstract]	'
Schedule of stock option plan activity	'
		Exercise								Binomial		Forfeiture		Compensation
	Grant Date	Price			Shares			Vesting		Value		Factor		Expense
	9/5/13	$	3.76			285,000		Immediate			0.18		0.87	$	44,631
	9/5/13	$	4.14			50,000		Immediate			0.18		0.87	$	7,830
	9/5/13	$	3.76			88,677		1 year			0.18		0.85	$	13,568
	9/5/13	$	4.14			5,667		1 year			0.18		0.85	$	867
	9/5/13	$	3.76			88,666		2 years			0.3		0.7225	$	19,218
	9/5/13	$	4.14			5,667		2 years			0.3		0.7225	$	1,228
	9/5/13	$	3.76			88,657		3 years			0.41		0.6141	$	22,323
	9/5/13	$	4.14			5,666		3 years			0.41		0.6141	$	1,427
	9/30/13	$	3.76			8,000		Immediate			0.33		0.87	$	2,297
	10/28/13	$	3.76			14,000		1 year			0.33		0.85	$	3,927
	10/28/13	$	3.76			14,000		2 years			0.46		0.7225	$	4,653
	10/28/13	$	3.76			14,000		3 years			0.57		0.6141	$	4,901
	11/18/13	$	3.76			8,334		1 year			0.33		0.85	$	2,338
	11/18/13	$	3.76			8,333		2 years			0.46		0.7225	$	2,769
	11/18/13	$	3.76			8,333		3 years			0.57		0.6141	$	2,917
	12/12/13	$	3.76			60,000		Immediate			0.33		0.87	$	17,226
	12/12/13	$	3.76			34,000		1 year			0.33		0.85	$	9,537
	12/12/13	$	3.76			34,000		2 years			0.46		0.7225	$	11,300
	12/12/13	$	3.76			34,000		3 years			0.57		0.6141	$	11,901
						855,000
Schedule of outstanding stock options	'
		Vested			Un-vested				Total
	Balance as of December 31, 2013		375,500			423,500				799,000
	Granted during the year		-			-				-
	Exercised during the year		-			-				-
	Forfeited during the year		(20,000	)		(32,500	)			(52,500	)
	Expired during the year		-			-				-
	Balance as of March 31, 2014		355,500			391,000				746,500

Commitments_Tables

Commitments (Tables)	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies [Abstract]	'
Summary of minimum lease payments under the lease agreement	'
	Nine months ending December 31, 2014		78,000
	2015		70,000
	Total	$	148,000

Guarantees_of_Secured_Debentur1

Guarantees of Secured Debentures (Tables)	3 Months Ended
	Mar. 31, 2014
Guarantees of Secured Debentures [Abstract]	'
Condensed Consolidating Balance Sheets	'
	March 31, 2014	Parent				Guarantor Sub			Non-Guarantor Sub			Eliminations				Consolidated
	A S S E T S
	Cash and cash equivalents		$	26,466,468			$	1,616,831		$	-		$	-			$	28,083,299
	Restricted cash			-				350,000			2,503,763			-				2,853,763
	Investment in life settlements, at fair     value			-				-			254,503,535			-				254,503,535
	Other assets			395,201				723,040			1,018,425			-				2,136,666
	Investment in subsidiaries			148,405,194				177,845,326			-			(326,250,520	)			-
	TOTAL ASSETS		$	175,266,863			$	180,535,197		$	258,025,723		$	(326,250,520	)		$	287,577,263
	L I A B I L I T I E S & S T O C K H O L D E R S’ E Q U I T Y (D E F I C I T)
	LIABILITIES
	Revolving credit facility		$	-			$	-		$	79,000,000		$	-			$	79,000,000
	Series I Secured notes payable			-				28,602,238			-			-				28,602,238
	Secured renewable debentures			145,989,431				-			-			-				145,989,431
	Interest payable			4,584,861				3,143,600			670,731			-				8,399,192
	Accounts payable and other accrued expenses			399,308				384,165			509,666			-				1,293,139
	Deferred taxes			6,720,316				-			-			-				6,720,316
	TOTAL LIABILITIES			157,693,916				32,130,003			80,180,397			-				270,004,316
	CONVERTIBLE, REDEEMABLE PREFERRED STOCK			25,036,056				-			-			-				25,036,056
	STOCKHOLDERS’ EQUITY (DEFICIT)
	Member capital			-				148,405,194			177,845,326			(326,250,520	)			-
	Common stock			9,124				-			-			-				9,124
	Additional paid-in capital			2,867,514				-			-			-				2,867,514
	Accumulated deficit			(10,339,747	)			-			-			-				(10,339,747	)
	TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)			(7,463,109	)			148,405,194			177,845,326			(326,250,520	)			(7,463,109	)
	TOTAL LIABILITIES AND EQUITY (DEFICIT)		$	175,266,863			$	180,535,197		$	258,025,723		$	(326,250,520	)		$	287,577,263
		Parent				Guarantor Subsidiary			Non-Guarantor Subsidiaries			Eliminations				Consolidated
	31-Dec-13
	A S S E T S
	Cash and cash equivalents	$	32,711,636			$	738,157		$	-		$	-			$	33,449,793
	Restricted cash		-				1,420,000			4,412,970			-				5,832,970
	Investment in life settlements, at fair value		-				-			234,672,794			-				234,672,794
	Other assets		381,883				484,510			558,526			-				1,424,919
	Investment in subsidiaries		129,839,241				159,798,490			-			(289,637,731	)			-
	TOTAL ASSETS	$	162,932,760			$	162,441,157		$	239,644,290		$	(289,637,731	)		$	275,380,476
	L I A B I L I T I E S  &  S T O C K H O L D E R S'  E Q U I T Y  (D E F I C I T)
	LIABILITIES
	Revolving credit facility	$	-			$	-		$	79,000,000		$	-			$	79,000,000
	Series I Secured notes payable		-				29,275,202			-			-				29,275,202
	Renewable Secured Debentures		131,646,062				-			-			-				131,646,062
	Interest payable		3,806,820				3,065,465			337,123			-				7,209,408
	Accounts payable and other accrued expenses		574,026				261,249			508,667			-				1,343,952
	Deferred taxes		7,675,174				-			-			-				7,675,174
	TOTAL LIABILITIES		143,702,082				32,601,916			79,845,800			-				256,149,798
	CONVERTIBLE, REDEEMABLE PREFERRED STOCK		24,722,693				-			-			-				24,722,693
	STOCKHOLDERS’ EQUITY (DEFICIT)
	Member capital		-				129,839,241			159,798,490			(289,637,731	)			-
	Common stock		9,124				-			-			-				9,124
	Additional paid-in capital		2,937,438				-			-			-				2,937,438
	Accumulated deficit		(8,438,577	)			-			-			-				(8,438,577	)
	TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)		(5,492,015	)			129,839,241			159,798,490			(289,637,731	)			(5,492,015	)
	TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$	162,932,760			$	162,441,157		$	239,644,290		$	(289,637,731	)		$	275,380,476
Condensed Consolidating Statements of Operations	'
	For the three months ended March 31, 2014	Parent				Guarantor			Non-Guarantor			Eliminations				Consolidated
						Subsidiary			Subsidiaries
	REVENUE
	Contract servicing fees	$	-			$	966,056		$	-		$	(966,056	)		$	-
	Gain on life settlements, net		-				-			5,516,205			-				5,516,205
	Interest and other income		6,929				169,615			44			(169,221	)			7,367
	TOTAL REVENUE		6,929				1,135,671			5,516,249			(1,135,277	)			5,523,572
	EXPENSES
	Origination and servicing fees		-				-			966,056			(966,056	)			-
	Employee compensation and benefits		590,584				378,162			-			-				968,746
	Legal and professional fees		266,159				59,139			-			-				325,298
	Interest expense		4,216,528				778,567			1,331,453			-				6,326,548
	Other expenses		421,243				325,255			181,731			(169,221	)			759,008
	TOTAL EXPENSES		5,494,514				1,541,123			2,479,240			(1,135,277	)			8,379,600
	INCOME (LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES		(5,487,585	)			(405,452	)		3,037,009			-				(2,856,028	)
	EQUITY IN INCOME OF SUBSIDIARY		2,631,557				3,037,009			-			(5,668,566	)			-
	NET INCOME (LOSS) BEFORE INCOME TAXES		(2,856,028	)			2,631,557			3,037,009			(5,668,566	)			(2,856,028	)
	INCOME TAX BENEFIT		(954,858	)			-			-			-				(954,858	)
	NET INCOME (LOSS)	$	(1,901,170	)		$	2,631,557		$	3,037,009		$	(5,668,566	)		$	(1,901,170	)
	For the three months ended March 31, 2013	Parent				Guarantor			Non-Guarantor			Eliminations				Consolidated
						Subsidiary			Subsidiaries
	REVENUE
	Contract servicing fees	$	-			$	1,278,102		$	-		$	(1,278,102	)		$	-
	Gain on life settlements, net		-				-			8,340,356			-				8,340,356
	Interest and other income		8,091				136,569			23,010			-				167,670
	TOTAL REVENUE		8,091				1,414,671			8,363,366							8,508,026
	EXPENSES
	Origination and servicing fees		-				-			1,278,102			(1,278,102	)			-
	Employee compensation and benefits		1,546,702				390,718			-			-				1,937,420
	Legal and professional fees		399,523				37,767			-			-				437,290
	Interest expense		2,321,169				907,175			1,238,871			-				4,467,215
	Other expenses		634,155				386,490			12,499			-				1,033,144
	TOTAL EXPENSES		4,901,549				1,722,150			2,529,472			(1,278,102	)			7,875,069
	INCOME (LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES		(4,893,458	)			(307,479	)		5,883,894			-				632,957
	EQUITY IN INCOME OF SUBSIDIARY		5,526,115				5,882,414			-			(11,408,529	)			-
	NET INCOME BEFORE INCOME TAXES		632,657				5,574,935			5,833,894			(11,408,529	)			632,957
	INCOME TAX EXPENSE		565,523				300			-			-				565,823
	NET INCOME	$	67,134			$	5,574,635		$	5,833,894		$	(11,408,529	)		$	67,134
Condensed Consolidating Statements of Cash Flows	'
	For the three months ended March 31, 2014	Parent				Guarantor Sub			Non-Guarantor Sub			Eliminations				Consolidated
	CASH FLOWS FROM OPERATING ACTIVITIES
	Net income (loss)	$	(1,901,170	)		$	2,631,557		$	3,037,009		$	(5,668,566	)		$	(1,901,170	)
	Adjustments to reconcile net loss to cash:
	(Equity) loss of subsidiaries		(2,631,557	)			(3,037,009	)		-			5,668,566				-
	Life settlements – change in fair value		-				-			(11,358,913	)		-				(11,358,913	)
	Amortization of deferred financing and issuance costs		847,236				166,946			(660,525	)		-				353,657
	Deferred income taxes		(954,858	)			-			-			-				(954,858	)
	Preferred stock issued for dividends		192,340				-			-			-				192,340
	(Increase) in operating assets:
	Other assets		(15,947,713	)			(15,248,357	)		-			30,944,224				(251,846	)
	Increase in operating liabilities:
	Accounts payable and other accrued expenses		713,785				229,443			334,598			-				1,277,826
	NET CASH FLOWS USED IN OPERATING ACTIVITIES		(19,681,937	)			(15,257,420	)		(8,647,831	)		30,944,224				(12,642,964	)
	CASH FLOWS FROM INVESTING ACTIVITIES
	Investment in life settlements		-				-			(8,271,203	)		-				(8,271,203	)
	NET CASH FLOWS USED IN INVESTING ACTIVITIES		-				-			(8,271,203	)		-				(8,271,203	)
	CASH FLOWS FROM FINANCING ACTIVITIES
	Payments for redemption of Series I Secured notes payable		-				(868,303	)		-			-				(868,303	)
	Proceeds from issuance of debentures		18,365,657				-			-			-				18,365,657
	Payments for issuance costs and redemption of Renewable Secured Debentures		(4,928,888	)			-			-			-				(4,928,888	)
	Proceeds from restricted cash		-				1,070,000			1,909,207			-				2,979,207
	Issuance of member capital		-				15,934,397			15,009,827			(30,944,224	)			-
	NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		13,436,769				16,136,094			16,919,034			(30,944,224	)			15,547,673
	NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(6,245,168	)			878,674			-			-				(5,366,494	)
	CASH AND CASH EQUIVALENTS
	BEGINNING OF THE PERIOD		32,711,636				738,157			-			-				33,449,793
	END OF THE PERIOD	$	26,466,468			$	1,616,831		$	-		$	-			$	28,083,299
	For the three months ended March 31, 2013	Parent				Guarantor Sub			Non-Guarantor Sub			Eliminations				Consolidated
	CASH FLOWS FROM OPERATING ACTIVITIES
	Net income	$	67,134			$	5,574,635		$	5,833,894		$	(11,408,529	)		$	67,134
	Adjustments to reconcile net loss to cash:
	(Equity) loss of subsidiaries		(5,526,115	)			(5,882,414	)		-			11,408,529				-
	Life settlements – change in fair value		-				-			(11,494,725	)		-				(11,494,725	)
	Amortization of deferred financing and issuance costs		393,477				272,505			427,765			-				1,093,747
	Deferred income taxes		563,874				-			-			-				563,874
	Preferred stock issued for dividends		83,702				-			-			-				83,702
	(Increase) decrease in operating assets:
	Other assets		(14,274,237	)			(10,700,326	)		669,198			24,856,539				551,174
	Increase in operating liabilities:
	Accounts payable and other accrued expenses		844,042				131,527			315,187			-				1,290,756
	NET CASH FLOWS USED IN OPERATING ACTIVITIES		(17,848,123	)			(10,604,073	)		(4,248,681	)		24,856,539				(7,844,338	)
	CASH FLOWS FROM INVESTING ACTIVITIES
	Investment in life settlements		-				-			(9,913,049	)		-				(9,913,049	)
	Proceeds from settlement of life settlements		-				-			1,490,000			-				1,490,000
	NET CASH FLOWS USED IN INVESTING ACTIVITIES		-				-			(8,423,049	)		-				(8,423,049	)
	CASH FLOWS FROM FINANCING ACTIVITIES
	Net proceeds from revolving credit facility		-				-			8,000,000			-				8,000,000
	Payments for redemption of Series I Secured notes payable		-				(1,507,824	)		-			-				(1,507,824	)
	Proceeds from issuance of debentures		23,850,794				-			-			-				23,850,794
	Payments for issuance costs and redemption of Renewable Secured Debentures		(2,303,268	)			-			-			-				(2,303,268	)
	Proceeds (payments) from restricted cash		-				1,469,676			(6,000,784	)		-				(4,531,108	)
	Payments for redemption of preferred stock		(186,669	)													(186,669	)
	NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		21,360,857				14,145,877			12,671,730			(24,856,539	)			23,321,925
	NET INCREASE IN CASH AND CASH EQUIVALENTS		3,512,734				3,541,804			-			-				7,054,538
	CASH AND CASH EQUIVALENTS
	BEGINNING OF THE PERIOD		25,035,579				2,461,465			-			-				27,497,044
	END OF THE PERIOD	$	28,548,313			$	6,003,269		$	-		$	-			$	34,551,582

Concentrations_Tables

Concentrations (Tables)	3 Months Ended
	Mar. 31, 2014
Concentrations [Abstract]	'
Summary of the face value of insurance contracts with specific life insurance companies exceeding 10% of the total face value held by the Company	'
		March 31,			December 31,
			2014			2013
	Life insurance company		%			%
	Company A			15.98			16.58
	Company B			11.13			11.34
Summary of the number of insurance contracts held in specific states exceeding 10% of the total face value held by the Company	'
			March 31,			December 31,
			2014			2013
	State of residence		%			%
	California			27.97			28.14
	Florida			15.38			15.59
	New York			10.84			10.65

Nature_of_Business_and_Summary2

Nature of Business and Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Nature of business and summary of significant accounting policies (Textual)	'	'	'
Deposits and direct cost advances	$0	'	$201,000
Amortization of deferred financing costs	89,000	187,000	'
Future amortization of Financing cost for year ending December 31, 2014	$268,000	'	'
Redemption Period for amortization of discount related to financing cost	'3 years	'	'

Restrictions_on_Cash_Details

Restrictions on Cash (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Restrictions on Cash (Textual)	'	'
Restricted cash	$2,854,000	$5,833,000

Investment_in_Life_Insurance_P2

Investment in Life Insurance Policies (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
	Contract	Contract
Summary of Company's life insurance policies accounted for under fair value method and their estimated maturity dates, based on remaining life expectancy	'	'
Number of Contracts, 2014	'	'
Number of Contracts, 2015	4	4
Number of Contracts, 2016	11	8
Number of Contracts, 2017	29	25
Number of Contracts, 2018	30	33
Number of Contracts, 2019	41	34
Number of Contracts, 2020	37	34
Number of Contracts, Thereafter	134	125
Life Settlement Contracts, Number of Contracts, Total	286	263
Estimated Fair Value, 2014	'	'
Estimated Fair Value, 2015	5,238,000	5,065,000
Estimated Fair Value, 2016	10,610,000	8,174,000
Estimated Fair Value, 2017	32,186,000	33,345,000
Estimated Fair Value, 2018	34,573,000	37,243,000
Estimated Fair Value, 2019	43,654,000	32,844,000
Estimated Fair Value, 2020	30,497,000	27,741,000
Estimated Fair Value, Thereafter	97,746,000	90,261,000
Life Settlement Contracts, Estimated Fair Value, Total	254,504,000	234,673,000
Face Value, 2014	'	'
Face Value, 2015	6,750,000	6,750,000
Face Value, 2016	16,800,000	13,750,000
Face Value, 2017	59,916,000	63,916,000
Face Value, 2018	71,017,000	80,318,000
Face Value, 2019	113,795,000	89,295,000
Face Value, 2020	81,014,000	75,644,000
Face Value, Thereafter	422,648,000	410,975,000
Life Settlement Contracts, Face Value, Total	$771,940,000	$740,648,000

Investment_in_Life_Insurance_P3

Investment in Life Insurance Policies (Details 1) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Summary of reconciliation of gain on life settlements	'	'
Change in fair value	$11,359,000	$11,495,000
Premiums and other annual fees	-5,843,000	-5,665,000
Policy maturities	'	2,510,000
Gain on life settlements, net	$5,516,000	$8,340,000

Investment_in_Life_Insurance_P4

Investment in Life Insurance Policies (Details 2) (USD $)	Mar. 31, 2014
Summary of estimated expected premium payments to maintain the above life insurance policies assuming no mortalities	'
Nine months ending December 31 ,2014	$17,882,000
2015	26,078,000
2016	28,550,000
2017	32,109,000
2018	35,155,000
Estimated expected premium payments	$139,774,000

Investment_in_Life_Insurance_P5

Investment in Life Insurance Policies (Details Textual) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Investment in Life Insurance Policies (Textual)	'	'	'
Discount rate applied to portfolio	11.69%	'	11.69%
Benefit recognized from insurance policy	$0	$4,000,000	'
Carrying value of life insurance policy	0	1,490,000	'
Realized gains from life insurance policy	$0	$2,510,000	'

Fair_Value_Definition_and_Hier2

Fair Value Definition and Hierarchy (Details) (Life Insurance policies [Member], USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Life Insurance policies [Member]	'	'
Summary of reconciliation of investments in life insurance policies	'	'
Beginning balance	$234,673,000	$164,317,000
Purchases	8,472,000	10,698,000
Maturities (acquisition cost)	'	-1,490,000
Gross unrealized gains	11,359,000	11,616,000
Gross unrealized losses	'	-121,000
Ending balance	$254,504,000	$185,020,000

Fair_Value_Definition_and_Hier3

Fair Value Definition and Hierarchy (Details 1) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Summary of inputs utilized in estimating the fair value	'		'		'
Weighted average life expectancy, months*	'		'79 years 4 months 24 days		'80 months 27 days
Discount rate	11.69%		11.69%		'
Life Insurance policies [Member]	'		'		'
Summary of inputs utilized in estimating the fair value	'		'		'
Weighted average age of insured	'82 years 3 months 18 days		'82 years 1 month 6 days		'
Weighted average life expectancy, months*	'84 years 3 months 18 days	[1]	'87 months	[1]	'
Average face amount per policy	2,699,000		2,816,000		'
Discount rate	11.69%		11.69%		'
[1]	* Standard life expectancy as adjusted for insured's specific circumstances.

Fair_Value_Definition_and_Hier4

Fair Value Definition and Hierarchy (Details 2) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Plus 8 months [Member]	'	'
Fair value sensitivity analysis on the investment in life insurance policies	'	'
Investment in life policies	($36,833,000)	($34,382,000)
Minus 8 months [Member]	'	'
Fair value sensitivity analysis on the investment in life insurance policies	'	'
Investment in life policies	38,756,000	36,152,000
Plus 4 Months [Member]	'	'
Fair value sensitivity analysis on the investment in life insurance policies	'	'
Investment in life policies	-18,658,000	-17,417,000
Minus 4 Months [Member]	'	'
Fair value sensitivity analysis on the investment in life insurance policies	'	'
Investment in life policies	19,145,000	17,865,000
Plus 2% [Member]	'	'
Fair value sensitivity analysis on the investment in life insurance policies	'	'
Investment in life policies	-23,949,000	-22,944,000
Minus 2% [Member]	'	'
Fair value sensitivity analysis on the investment in life insurance policies	'	'
Investment in life policies	28,161,000	27,063,000
Plus 1% [Member]	'	'
Fair value sensitivity analysis on the investment in life insurance policies	'	'
Investment in life policies	-12,446,000	-11,933,000
Minus 1% [Member]	'	'
Fair value sensitivity analysis on the investment in life insurance policies	'	'
Investment in life policies	$13,496,000	$12,959,000

Fair_Value_Definition_and_Hier5

Fair Value Definition and Hierarchy (Details 3) (Level 3 [Member], USD $)	3 Months Ended
	Mar. 31, 2014
Warrants Level 3 instruments and measured at fair value upon issuance	'
Warrants issued	831,908
December 2011 [Member]	'
Warrants Level 3 instruments and measured at fair value upon issuance	'
Warrants issued date	31-Dec-11
Warrants issued	137,874
Fair value per share	0.11
Risk free rate	0.42%
Volatility rate	25.25%
Term	'3 years
March 2012 [Member]	'
Warrants Level 3 instruments and measured at fair value upon issuance	'
Warrants issued date	31-Mar-12
Warrants issued	76,260
Fair value per share	0.26
Risk free rate	0.38%
Volatility rate	36.20%
Term	'3 years
June 2012 [Member]	'
Warrants Level 3 instruments and measured at fair value upon issuance	'
Warrants issued date	30-Jun-12
Warrants issued	323,681
Fair value per share	0.58
Risk free rate	0.41%
Volatility rate	47.36%
Term	'3 years
July 2012 [Member]	'
Warrants Level 3 instruments and measured at fair value upon issuance	'
Warrants issued date	31-Jul-12
Warrants issued	289,093
Fair value per share	0.58
Risk free rate	0.41%
Volatility rate	47.36%
Term	'3 years
September 2012 [Member]	'
Warrants Level 3 instruments and measured at fair value upon issuance	'
Warrants issued date	30-Sep-12
Warrants issued	5,000
Fair value per share	0.36
Risk free rate	0.31%
Volatility rate	40.49%
Term	'3 years

Fair_Value_Definition_and_Hier6

Fair Value Definition and Hierarchy (Details Textual) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
			Policy
Fair Value Definition and Hierarchy (Textual)	'	'	'
Percentage increase in life expectancy	'	'	8.67%
Percentage of effective change in life expectancy	'	'	4.33%
Decrease in fair value portfolio of life insurance policies	'	'	$12,400,000
Number of policies owned	'	'	211
Description for change in discount factor	'If the life expectancies were increased or decreased by four and eight months on each outstanding policy and the discount factors were increased or decreased by 1% and 2%, while all other variables are held constant.	'	'
Increase decrease in life expectancy	'Four and eight months	'	'
Increase decrease in discount rate	'1% and 2	'	'
Average rolled down life expectancy	'	'79 years 4 months 24 days	'80 months 27 days
Description of average roll down life expectancty	'	'Eight and one-half months	'
Description of average updated life expectancty	'	'One and one- half months	'
Estimated fair value of Series I Secured notes payable	'	180,912,000	'
Weighted average market interest rate of Secured notes payable	'	7.09%	'
Face value of notes	$178,289,000	'	'

Notes_Receivable_from_Related_1

Notes Receivable from Related Parties (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Notes Receivable from Related Parties (Textual)	'	'
Receivables due from an affiliate, Opportunity Finance, LLC	$5,000,000	$5,000,000

Credit_Facilities_Details

Credit Facilities (Details) (USD $)	0 Months Ended		3 Months Ended		12 Months Ended
	Jan. 29, 2013	Jul. 15, 2008	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Credit Facilities (Textual)	'	'	'	'	'
Maximum borrowing amount under line of credit facility	'	$100,000,000	'	'	'
Expiry date of line of credit	'	15-Jul-13	'	'	'
Extended date of line of credit facility	31-Dec-14	'	'	'	'
Amount outstanding under line of credit facility	'	'	79,000,000	'	79,000,000
Effective rate of interest	'	'	6.21%	'	6.19%
Weighted average effective interest rate	'	'	6.22%	5.86%	'
Minimum tangible net worth to be maintained by company	'	'	'	'	15,000,000
Consolidated net income under credit and security agreement	'	'	22,498,000	'	'
Consolidated tangible net worth under credit and security agreement	'	'	58,865,000	'	'
Total funds available for additional borrowings under the borrowing base formula criteria	'	'	$4,740,000	'	$3,937,000

Series_I_Secured_Notes_Payable2

Series I Secured Notes Payable (Details) (Series I Secured Notes Payable [Member], USD $)	Mar. 31, 2014
Series I Secured Notes Payable [Member]	'
Summary of future contractual maturities of series I secured notes payable	'
Nine months ending December 31 ,2014	$8,323,000
2015	8,638,000
2016	7,193,000
2017	4,252,000
2018	754,000
Thereafter	64,000
Total	$29,224,000

Series_I_Secured_Notes_Payable3

Series I Secured Notes Payable (Details Textual) (USD $)	0 Months Ended	3 Months Ended
	Jun. 14, 2011	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Series I Secured Notes Payable (Textual)	'	'	'	'
Weighted average market interest rate of Secured notes payable	'	'	'	7.09%
principal amount outstanding under Series I Secured notes	'	$145,989,431	'	$131,646,062
Amortization of deferred financing and issuance costs	'	89,000	187,000	'
Series I Secured Notes Payable [Member]	'	'	'	'
Series I Secured Notes Payable (Textual)	'	'	'	'
Minimum maturity period of secured notes	'6 months	'	'	'
Maximum maturity period of secured notes	'7 years	'	'	'
Interest rate on secured notes, Minimum	5.65%	'	'	'
Interest rate on secured notes, Maximum	9.55%	'	'	'
Description of interest payment	'	'Interest is payable monthly, quarterly, annually or at maturity depending on the terms of the note.	'	'
Weighted average market interest rate of Secured notes payable	'	8.35%	'	8.35%
principal amount outstanding under Series I Secured notes	'	29,224,000	'	29,744,000
Amortization of deferred financing and issuance costs	'	167,000	55,000	'
Future expected amortization of deferred financing costs	'	$622,000	'	'
Conditions for proceed from issuance of debenture	'	'(1) payment of commissions of Series I Secured note sales, (2) purchase life insurance policies, (3) pay premiums of life insurance policies, (4) pay principal and interest to Senior Liquidity Provider (DZ Bank), (5) pay portfolio or note operating fees or costs, (6) pay trustee (Wells Fargo Bank, N.A.), (7) pay servicer and collateral fees, (8) pay principal and interest on Series I Secured notes, (9) make distributions to equity holders for tax liability related to portfolio, (10) purchase interest rate caps, swaps, or hedging instruments, (11) pay GWG Series I Trustee fees, and (12) pay offering expenses.	'	'
Amortizatoin period of deferred financing cost	'	'6 years	'	'
Extension of Series I Secured notes maturity term description	'	'Under the amended and restated agreement, GWG may extend the maturity of Series I Secured notes of a six month term for up to two additional six month terms, and Series I Secured notes of a one year term for up to six months.	'	'

Renewable_Secured_Debentures_D

Renewable Secured Debentures (Details) (Renewable Secured Debentures [Member], USD $)	Mar. 31, 2014
Renewable Secured Debentures [Member]	'
Summary of Future maturities of renewable secured debentures	'
Nine months ending December 31 ,2014	$31,109,000
2015	44,587,000
2016	34,623,000
2017	13,094,000
2018	6,779,000
Thereafter	18,873,000
Total	$149,065,000

Renewable_Secured_Debentures_D1

Renewable Secured Debentures (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Renewable Secured Debentures (Textual)	'	'	'
Debentures offer for sale	$178,289,000	'	'
Weighted average market interest rate of Secured notes payable	'	'	7.09%
Proceeds from Issuance of Secured Debt	18,365,657	23,850,794	'
Renewable Secured Debentures [Member]	'	'	'
Renewable Secured Debentures (Textual)	'	'	'
Debentures offer for sale	250,000,000	'	'
Maturity period of debentures, Minimum	'6 months	'	'
Maturity period of debentures, Maximum	'7 years	'	'
Interest rates, minimum	4.75%	'	'
Interest rates, maximum	9.50%	'	'
Description of interest payment	'Interest is payable monthly, annually or at maturity depending on the terms of the debenture.	'	'
Weighted average market interest rate of Secured notes payable	7.53%	'	7.53%
Amount outstanding under Renewable Secured Debentures	149,065,000	'	134,891,000
Amortization of deferred issuance costs	84,700	278,000	'
Future expected amortization of deferred financing costs	5,418,000	'	'
Conditions for proceed from issuance of debenture	'(1) payment of commissions on sales of Renewable Secured Debentures, (2) payment of offering expenses, (3) purchase of life insurance policies, (4) Payment of premiums on life insurance policies, (5) payment of principal and interest on Renewable Secured Debentures, (6) payment of portfolio operations expenses, and (7) for general working capital.	'	'
Proceeds from Issuance of Secured Debt	$4,922,000	'	'

Convertible_Redeemable_Preferr1

Convertible, Redeemable Preferred Stock (Details) (USD $)	3 Months Ended		12 Months Ended	0 Months Ended	1 Months Ended	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Sep. 02, 2012	Jul. 31, 2011	Mar. 31, 2014
				Series A 10 % convertible Preferred Stock [Member]	Series A 10 % convertible Preferred Stock [Member]	Series A 10 % convertible Preferred Stock [Member]
Convertible, Redeemable Preferred Stock (Textual)	'	'	'	'	'	'
Company offering shares of convertible redeemable preferred stock	'	'	'	'	3,333,333	'
Series A preferred stock shares sold for cash	'	'	'	3,278,000	'	'
Consideration received on sale of Series A preferred stock	'	'	'	$24,582,000	'	'
Series A preferred stock shares issued in conversion of dividends	'	'	'	'	'	193,000
Series A preferred stock value issued in conversion of dividends	'	'	'	'	'	1,350,000
Offering price of series A preferred stock	'	'	'	'	'	$7.50
Series A preferred stock, Dividend rate	'	'	'	'	'	10.00%
Conversion term for series A preferred stock	'	'	'	'	'	'Each share has the right to convert into 1.5 shares of the Company's common stock.
Maturity period of warrant	'3 years	'	'	'	'	'
Exercise price of warrants	$6.25	'	'	'	'	'
Conversion of Series A preferred stock into common stock, description	'One share of common stock for every 20 shares of Series A preferred stock purchased.	'	'	'	'	'
Redemption price of preferred shares	'Stated value of $7.50 per share, plus accrued dividends.	'	'	'	'	'
Percentage of unredeemed shares redeemed one year after issuance	33.00%	'	'	'	'	'
Percentage of unredeemed shares redeemed two year after issuance	66.00%	'	'	'	'	'
Percentage of unredeemed shares redeemed three year after issuance	100.00%	'	'	'	'	'
Redemption price of shares	'The Company may redeem the Series A preferred shares at a price equal to 110% of their liquidation preference ($7.50 per share) at any time after December 15, 2012.	'	'	'	'	'
Preferred stock, liquidation preference per share	$7.50	'	'	'	'	'
Minimum offering price of common stock	$5.50	'	'	'	'	'
Aggregate gross proceeds of common Stock	5,000,000	'	'	'	'	'
Preferred Stock, Shares Issued	3,395,000	'	'	'	'	'
Proceeds from issuance of convertible preferred stock	25,364,000	'	'	'	'	'
Series A preferred stock issuance costs	2,838,000	'	'	'	'	'
Amortization of stock issuance costs	2,510,000	'	'	'	'	'
Net preferred stock capital balance	25,036,000	'	'	'	'	'
Fair value of outstanding warrants attached to Series A preferred stock	395,000	'	'	'	'	'
Term of redemption of warrants prior to expiration	'The Company may redeem outstanding warrants prior to their expiration, at a price of $0.01 per share upon 30 days written notice to the investors at any time after (i) the Company has completed a registration of its common stock with the SEC and (ii) the volume of weighted average sale price per share of common stock equals or exceeds $7.00 per share for ten consecutive trading days ending on the third business day prior to proper notice of such redemption.	'	'	'	'	'
Warrant outstanding	831,909	'	831,909	'	'	'
Weighted average remaining life of warrants outstanding	'1 year 1 month 6 days	'	'1 year 4 months 2 days	'	'	'
Declared and accrued dividends	634,000	635,000	'	'	'	'
Preferred stock issued in lieu of cash dividend	27,000	12,000	'	'	'	'
Cash dividend rate, per share	$7	'	'	'	'	'
Accrued preferred dividend	$634,000	'	'	'	'	'
Payable date of accrued preferred dividends	15-Apr-14	'	'	'	'	'

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Income Taxes (Textual)	'	'
Current income taxes	'	$2,000
Income tax expenses (Benefit)	-954,858	565,823
Effective income tax rate	33.40%	89.40%
Accrual of non-deductible preferred stock dividend expense	$635,000	'

Common_Stock_Details

Common Stock (Details) (Purchase and Sale Agreement [Member], USD $)	0 Months Ended
	Jun. 28, 2013	Jul. 11, 2011
Common Stock Disclosure [Line Items]	'	'
Terms for acquisition of equity interest in subsidiary	'	'Holdings issued to Athena Securities Group, LTD (Athena) 989,000 shares of common stock, which was equal to 9.9% of the outstanding shares in the Company in exchange for shares equal to 9.9% of the outstanding shares in Athena Structured Funds, PLC (Athena Funds) and cash of $5,000.
Athena Securities Group Ltd [Member]	'	'
Common Stock Disclosure [Line Items]	'	'
Shares of common stock issued	865,000	989,000
Amount of cash paid under acquisition terms	'	$5,000
Retained Common Stock	'	$124,000

Stock_Incentive_Plan_Details

Stock Incentive Plan (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Schedule of stock options plan activity	'
Exercise Price	$4.14
Granted during the year	855,000
Vesting	'3 years
Compensation Expense	$56,000
Grant Date One [Member]	'
Schedule of stock options plan activity	'
Grant Date	5-Sep-13
Exercise Price	$3.76
Granted during the year	285,000
Binominal Value	0.18
Forfeiture Factor	0.87
Compensation Expense	44,631
Grant Date Two [Member]	'
Schedule of stock options plan activity	'
Grant Date	5-Sep-13
Exercise Price	$4.14
Granted during the year	50,000
Binominal Value	0.18
Forfeiture Factor	0.87
Compensation Expense	7,830
Grant Date Three [Member]	'
Schedule of stock options plan activity	'
Grant Date	5-Sep-13
Exercise Price	$3.76
Granted during the year	88,677
Vesting	'1 year
Binominal Value	0.18
Forfeiture Factor	0.85
Compensation Expense	13,568
Grant Date Four [Member]	'
Schedule of stock options plan activity	'
Grant Date	5-Sep-13
Exercise Price	$4.14
Granted during the year	5,667
Vesting	'1 year
Binominal Value	0.18
Forfeiture Factor	0.85
Compensation Expense	867
Grant Date Five [Member]	'
Schedule of stock options plan activity	'
Grant Date	5-Sep-13
Exercise Price	$3.76
Granted during the year	88,666
Vesting	'2 years
Binominal Value	0.3
Forfeiture Factor	0.7225
Compensation Expense	19,218
Grant Date Six [Member]	'
Schedule of stock options plan activity	'
Grant Date	5-Sep-13
Exercise Price	$4.14
Granted during the year	5,667
Vesting	'2 years
Binominal Value	0.3
Forfeiture Factor	0.7225
Compensation Expense	1,228
Grant Date Seven [Member]	'
Schedule of stock options plan activity	'
Grant Date	5-Sep-13
Exercise Price	$3.76
Granted during the year	88,657
Vesting	'3 years
Binominal Value	0.41
Forfeiture Factor	0.6141
Compensation Expense	22,323
Grant Date Eight [Member]	'
Schedule of stock options plan activity	'
Grant Date	5-Sep-13
Exercise Price	$4.14
Granted during the year	5,666
Vesting	'3 years
Binominal Value	0.41
Forfeiture Factor	0.6141
Compensation Expense	1,427
Grant Date Nine [Member]	'
Schedule of stock options plan activity	'
Grant Date	30-Sep-13
Exercise Price	$3.76
Granted during the year	8,000
Binominal Value	0.33
Forfeiture Factor	0.87
Compensation Expense	2,297
Grant Date Ten [Member]	'
Schedule of stock options plan activity	'
Grant Date	28-Oct-13
Exercise Price	$3.76
Granted during the year	14,000
Vesting	'1 year
Binominal Value	0.33
Forfeiture Factor	0.85
Compensation Expense	3,927
Grant Date Eleven [Member]	'
Schedule of stock options plan activity	'
Grant Date	28-Oct-13
Exercise Price	$3.76
Granted during the year	14,000
Vesting	'2 years
Binominal Value	0.46
Forfeiture Factor	0.7225
Compensation Expense	4,653
Grant Date Twelve [Member]	'
Schedule of stock options plan activity	'
Grant Date	28-Oct-13
Exercise Price	$3.76
Granted during the year	14,000
Vesting	'3 years
Binominal Value	0.57
Forfeiture Factor	0.6141
Compensation Expense	4,901
Grant Date Thirteen[Member]	'
Schedule of stock options plan activity	'
Grant Date	18-Nov-13
Exercise Price	$3.76
Granted during the year	8,334
Vesting	'1 year
Binominal Value	0.33
Forfeiture Factor	0.85
Compensation Expense	2,338
Grant Date Fourteen[Member]	'
Schedule of stock options plan activity	'
Grant Date	18-Nov-13
Exercise Price	$3.76
Granted during the year	8,333
Vesting	'2 years
Binominal Value	0.46
Forfeiture Factor	0.7225
Compensation Expense	2,769
Grant Date Fifteen[Member]	'
Schedule of stock options plan activity	'
Grant Date	18-Nov-13
Exercise Price	$3.76
Granted during the year	8,333
Vesting	'3 years
Binominal Value	0.57
Forfeiture Factor	0.6141
Compensation Expense	2,917
Grant Date Sixteen[Member]	'
Schedule of stock options plan activity	'
Grant Date	12-Dec-13
Exercise Price	$3.76
Granted during the year	60,000
Binominal Value	0.33
Forfeiture Factor	0.87
Compensation Expense	17,226
Grant Date Seventeen [Member]	'
Schedule of stock options plan activity	'
Grant Date	12-Dec-13
Exercise Price	$3.76
Granted during the year	34,000
Vesting	'1 year
Binominal Value	0.33
Forfeiture Factor	0.85
Compensation Expense	9,537
Grant Date Eighteen [Member]	'
Schedule of stock options plan activity	'
Grant Date	12-Dec-13
Exercise Price	$3.76
Granted during the year	34,000
Vesting	'2 years
Binominal Value	0.46
Forfeiture Factor	0.7225
Compensation Expense	11,300
Grant Date Nineteen [Member]	'
Schedule of stock options plan activity	'
Grant Date	12-Dec-13
Exercise Price	$3.76
Granted during the year	34,000
Vesting	'3 years
Binominal Value	0.57
Forfeiture Factor	0.6141
Compensation Expense	$11,901

Stock_Incentive_Plan_Details_1

Stock Incentive Plan (Details 1)	3 Months Ended
	Mar. 31, 2014
Outstanding stock options	'
Beginning Balance	831,909
Granted during the year	855,000
Ending Balance	831,909
Stock Option [Member]	'
Outstanding stock options	'
Beginning Balance, Vested	375,500
Granted during the year, Vested	'
Exercised during the year, Vested	'
Forfeited during the year, Vested	-20,000
Expired during the year, Vested	'
Ending Balance, Vested	355,500
Beginning Balance, Un-vested	423,500
Granted during the year, Un-vested	'
Exercised during the year, Un-vested	'
Forfeited during the year, Un-vested	-32,500
Expired during the year, Un-vested	'
Ending Balance, Un-vested	391,000
Beginning Balance	799,000
Granted during the year	'
Exercised during the year	'
Forfeited during the year	-52,500
Expired during the year	'
Ending Balance	746,500

Stock_Incentive_Plan_Details_T

Stock Incentive Plan (Details Textual) (USD $)	0 Months Ended	3 Months Ended
	Mar. 27, 2013	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of shares issued to employees, officers and directors	'	855,000
Number of options vested	'	403,000
Exercise Price	'	4.14
Options vesting period	'	'3 years
Compensation expense related to un-vested options not yet recognized	'	105,315
Compensation expense related to un-vested options, period of recognition	'	'2 years 9 months
Ownership Percentage	'	10.00%
Stock-based compensation cost	'	56,000
Common Stock [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of shares issued to employees, officers and directors	'	855,000
Others [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Exercise Price	'	3.76
2013 Stock Incentive Plan [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of shares issuable	2,000,000	'
Stock based compensation, Method used	'	'The expected volatility used in the Black-Scholes model valuation of options issued during the year was 19.73% annualized. The annual volatility rate is based on the standard deviation of the average continuously compounded rate of return of five selected comparable companies over the previous 52 weeks.
Expected volatility rate	'	19.73%
2013 Stock Incentive Plan [Member] | Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock option period	'10 years	'
2013 Stock Incentive Plan [Member] | Common Stock [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Maximum number of shares for an employee	400,000	'
Forfeited during the year, Percent	'	15.00%
Forfeited during the year	'	108,500

Commitments_Details

Commitments (Details) (USD $)	Mar. 31, 2014
Summary of minimum lease payments under the lease agreement	'
Nine months ending December 31, 2014	$78,000
2015	70,000
Total	$148,000

Commitments_Details_Textual

Commitments (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
	sqft
Commitments (Textual)	'	'
Lease expiration date	31-Aug-15	'
Office space in square feet	11,695	'
Rent expenses	$52,000	$48,000

Contingencies_Details

Contingencies (Details) (USD $)	Mar. 31, 2014
Contingencies (Textual)	'
Loaned to Opportunity Finance, LLC, Subject to clawback claims by the bankruptcy court	$1,000,000
Interest receivable from Opportunity Finance, LLC, Subject to clawback claims by the bankruptcy court	$177,000

Guarantees_of_Secured_Debentur2

Guarantees of Secured Debentures (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
A S S E T S	'	'	'	'
Cash and cash equivalents	$28,083,299	$33,449,793	$34,551,582	$27,497,044
Restricted cash	2,853,763	5,832,970	'	'
Investment in life settlements, at fair value	254,503,535	234,672,794	'	'
Other assets	2,136,666	1,424,919	'	'
Investment in subsidiaries	'	'	'	'
TOTAL ASSETS	287,577,263	275,380,476	'	'
LIABILITIES	'	'	'	'
Revolving credit facility	79,000,000	79,000,000	'	'
Series I Secured notes payable	28,602,238	29,275,202	'	'
Renewable Secured Debentures	145,989,431	131,646,062	'	'
Interest payable	8,399,192	7,209,408	'	'
Accounts payable and other accrued expenses	1,293,139	1,343,952	'	'
Deferred taxes	6,720,316	7,675,174	'	'
TOTAL LIABILITIES	270,004,316	256,149,798	'	'
CONVERTIBLE, REDEEMABLE PREFERRED STOCK	25,036,056	24,722,693	'	'
STOCKHOLDERS' EQUITY (DEFICIT)	'	'	'	'
Member capital	'	'	'	'
Common stock	9,124	9,124	'	'
Additional paid-in capital	2,867,514	2,937,438	'	'
Accumulated deficit	-10,339,747	-8,438,577	'	'
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	-7,463,109	-5,492,015	'	'
TOTAL LIABILITIES AND EQUITY (DEFICIT)	287,577,263	275,380,476	'	'
Parent [Member]	'	'	'	'
A S S E T S	'	'	'	'
Cash and cash equivalents	26,466,468	32,711,636	28,548,313	25,035,579
Restricted cash	'	'	'	'
Investment in life settlements, at fair value	'	'	'	'
Other assets	395,201	381,883	'	'
Investment in subsidiaries	148,405,194	129,839,241	'	'
TOTAL ASSETS	175,266,863	162,932,760	'	'
LIABILITIES	'	'	'	'
Revolving credit facility	'	'	'	'
Series I Secured notes payable	'	'	'	'
Renewable Secured Debentures	145,989,431	131,646,062	'	'
Interest payable	4,584,861	3,806,820	'	'
Accounts payable and other accrued expenses	399,308	574,026	'	'
Deferred taxes	6,720,316	7,675,174	'	'
TOTAL LIABILITIES	157,693,916	143,702,082	'	'
CONVERTIBLE, REDEEMABLE PREFERRED STOCK	25,036,056	24,722,693	'	'
STOCKHOLDERS' EQUITY (DEFICIT)	'	'	'	'
Member capital	'	'	'	'
Common stock	9,124	9,124	'	'
Additional paid-in capital	2,867,514	2,937,438	'	'
Accumulated deficit	-10,339,747	-8,438,577	'	'
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	-7,463,109	-5,492,015	'	'
TOTAL LIABILITIES AND EQUITY (DEFICIT)	175,266,863	162,932,760	'	'
Guarantor Sub [Member]	'	'	'	'
A S S E T S	'	'	'	'
Cash and cash equivalents	1,616,831	738,157	6,003,269	2,461,465
Restricted cash	350,000	1,420,000	'	'
Investment in life settlements, at fair value	'	'	'	'
Other assets	723,040	484,510	'	'
Investment in subsidiaries	177,845,326	159,798,490	'	'
TOTAL ASSETS	180,535,197	162,441,157	'	'
LIABILITIES	'	'	'	'
Revolving credit facility	'	'	'	'
Series I Secured notes payable	28,602,238	29,275,202	'	'
Renewable Secured Debentures	'	'	'	'
Interest payable	3,143,600	3,065,465	'	'
Accounts payable and other accrued expenses	384,165	261,249	'	'
Deferred taxes	'	'	'	'
TOTAL LIABILITIES	32,130,003	32,601,916	'	'
CONVERTIBLE, REDEEMABLE PREFERRED STOCK	'	'	'	'
STOCKHOLDERS' EQUITY (DEFICIT)	'	'	'	'
Member capital	148,405,194	129,839,241	'	'
Common stock	'	'	'	'
Additional paid-in capital	'	'	'	'
Accumulated deficit	'	'	'	'
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	148,405,194	129,839,241	'	'
TOTAL LIABILITIES AND EQUITY (DEFICIT)	180,535,197	162,441,157	'	'
Non-Guarantor Sub [Member]	'	'	'	'
A S S E T S	'	'	'	'
Cash and cash equivalents	'	'	'	'
Restricted cash	2,503,763	4,412,970	'	'
Investment in life settlements, at fair value	254,503,535	234,672,794	'	'
Other assets	1,018,425	558,526	'	'
Investment in subsidiaries	'	'	'	'
TOTAL ASSETS	258,025,723	239,644,290	'	'
LIABILITIES	'	'	'	'
Revolving credit facility	79,000,000	79,000,000	'	'
Series I Secured notes payable	'	'	'	'
Renewable Secured Debentures	'	'	'	'
Interest payable	670,731	337,123	'	'
Accounts payable and other accrued expenses	509,666	508,667	'	'
Deferred taxes	'	'	'	'
TOTAL LIABILITIES	80,180,397	79,845,800	'	'
CONVERTIBLE, REDEEMABLE PREFERRED STOCK	'	'	'	'
STOCKHOLDERS' EQUITY (DEFICIT)	'	'	'	'
Member capital	177,845,326	159,798,490	'	'
Common stock	'	'	'	'
Additional paid-in capital	'	'	'	'
Accumulated deficit	'	'	'	'
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	177,845,326	159,798,490	'	'
TOTAL LIABILITIES AND EQUITY (DEFICIT)	258,025,723	239,644,290	'	'
Eliminations [Member]	'	'	'	'
A S S E T S	'	'	'	'
Cash and cash equivalents	'	'	'	'
Restricted cash	'	'	'	'
Investment in life settlements, at fair value	'	'	'	'
Other assets	'	'	'	'
Investment in subsidiaries	-326,250,520	-289,637,731	'	'
TOTAL ASSETS	-326,250,520	-289,637,731	'	'
LIABILITIES	'	'	'	'
Revolving credit facility	'	'	'	'
Series I Secured notes payable	'	'	'	'
Renewable Secured Debentures	'	'	'	'
Interest payable	'	'	'	'
Accounts payable and other accrued expenses	'	'	'	'
Deferred taxes	'	'	'	'
TOTAL LIABILITIES	'	'	'	'
CONVERTIBLE, REDEEMABLE PREFERRED STOCK	'	'	'	'
STOCKHOLDERS' EQUITY (DEFICIT)	'	'	'	'
Member capital	-326,250,520	-289,637,731	'	'
Common stock	'	'	'	'
Additional paid-in capital	'	'	'	'
Accumulated deficit	'	'	'	'
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	-326,250,520	-289,637,731	'	'
TOTAL LIABILITIES AND EQUITY (DEFICIT)	($326,250,520)	($289,637,731)	'	'

Guarantees_of_Secured_Debentur3

Guarantees of Secured Debentures (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
REVENUE	'	'
Contract servicing fees	'	'
Gain on life settlements, net	5,516,205	8,340,356
Interest and other income	7,367	167,670
TOTAL REVENUE	5,523,572	8,508,026
EXPENSES	'	'
Origination and servicing fees	'	'
Employee compensation and benefits	968,746	1,937,420
Legal and professional fees	325,298	437,290
Interest expense	6,326,548	4,467,215
Other expenses	759,008	1,033,144
TOTAL EXPENSES	8,379,600	7,875,069
INCOME (LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES	-2,856,028	632,957
EQUITY IN INCOME OF SUBSIDIARY	'	'
NET INCOME (LOSS) BEFORE INCOME TAXES	-2,856,028	632,957
INCOME TAX BENEFIT	-954,858	565,823
NET INCOME (LOSS)	-1,901,170	67,134
Parent [Member]	'	'
REVENUE	'	'
Contract servicing fees	'	'
Gain on life settlements, net	'	'
Interest and other income	6,929	8,091
TOTAL REVENUE	6,929	8,091
EXPENSES	'	'
Origination and servicing fees	'	'
Employee compensation and benefits	590,584	1,546,702
Legal and professional fees	266,159	399,523
Interest expense	4,216,528	2,321,169
Other expenses	421,243	634,155
TOTAL EXPENSES	5,494,514	4,901,549
INCOME (LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES	-5,487,585	-4,893,458
EQUITY IN INCOME OF SUBSIDIARY	2,631,557	5,526,115
NET INCOME (LOSS) BEFORE INCOME TAXES	-2,856,028	632,657
INCOME TAX BENEFIT	-954,858	565,523
NET INCOME (LOSS)	-1,901,170	67,134
Guarantor Subsidiary [Member]	'	'
REVENUE	'	'
Contract servicing fees	966,056	1,278,102
Gain on life settlements, net	'	'
Interest and other income	169,615	136,569
TOTAL REVENUE	1,135,671	1,414,671
EXPENSES	'	'
Origination and servicing fees	'	'
Employee compensation and benefits	378,162	390,718
Legal and professional fees	59,139	37,767
Interest expense	778,567	907,175
Other expenses	325,255	386,490
TOTAL EXPENSES	1,541,123	1,722,150
INCOME (LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES	-405,452	-307,479
EQUITY IN INCOME OF SUBSIDIARY	3,037,009	5,882,414
NET INCOME (LOSS) BEFORE INCOME TAXES	2,631,557	5,574,935
INCOME TAX BENEFIT	'	300
NET INCOME (LOSS)	2,631,557	5,574,635
Non-Guarantor Subsidiaries [Member]	'	'
REVENUE	'	'
Contract servicing fees	'	'
Gain on life settlements, net	5,516,205	8,340,356
Interest and other income	44	23,010
TOTAL REVENUE	5,516,249	8,363,366
EXPENSES	'	'
Origination and servicing fees	966,056	1,278,102
Employee compensation and benefits	'	'
Legal and professional fees	'	'
Interest expense	1,331,453	1,238,871
Other expenses	181,731	12,499
TOTAL EXPENSES	2,479,240	2,529,472
INCOME (LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES	3,037,009	5,883,894
EQUITY IN INCOME OF SUBSIDIARY	'	'
NET INCOME (LOSS) BEFORE INCOME TAXES	3,037,009	5,833,894
INCOME TAX BENEFIT	'	'
NET INCOME (LOSS)	3,037,009	5,833,894
Eliminations [Member]	'	'
REVENUE	'	'
Contract servicing fees	-966,056	-1,278,102
Gain on life settlements, net	'	'
Interest and other income	-169,221	'
TOTAL REVENUE	-1,135,277	'
EXPENSES	'	'
Origination and servicing fees	-966,056	-1,278,102
Employee compensation and benefits	'	'
Legal and professional fees	'	'
Interest expense	'	'
Other expenses	-169,221	'
TOTAL EXPENSES	-1,135,277	-1,278,102
INCOME (LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES	'	'
EQUITY IN INCOME OF SUBSIDIARY	-5,668,566	-11,408,529
NET INCOME (LOSS) BEFORE INCOME TAXES	-5,668,566	-11,408,529
INCOME TAX BENEFIT	'	'
NET INCOME (LOSS)	($5,668,566)	($11,408,529)

Guarantees_of_Secured_Debentur4

Guarantees of Secured Debentures (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net income	($1,901,170)	$67,134
Adjustments to reconcile net income (loss) to cash flows from operating activities:	'	'
(Equity) loss of subsidiaries	'	'
Life settlements - change in fair value	-11,358,913	-11,494,725
Amortization of deferred financing and issuance costs	353,657	1,093,747
Deferred income taxes	-954,858	563,874
Preferred stock issued for dividends	192,340,000	83,702
(Increase) in operating assets:	'	'
Other assets	-251,846	551,174
Increase in operating liabilities:	'	'
Accounts payable and other accrued expenses	1,277,826	1,290,756
NET CASH FLOWS USED IN OPERATING ACTIVITIES	-12,642,964	-7,844,338
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Investment in life settlements	-8,271,203	-9,913,049
Proceeds from settlement of life settlements	'	1,490,000
NET CASH FLOWS USED IN INVESTING ACTIVITIES	-8,271,203	-8,423,049
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Net proceeds from revolving credit facility	'	8,000,000
Payments for redemption of Series I Secured notes payable	-868,303	-1,507,824
Proceeds from issuance of debentures	18,365,657	23,850,794
Payments for redemption of preferred stock	'	-186,669
Payments for issuance and redemption of Renewable Secured Debentures	4,928,888	2,303,268
Proceeds (payments) from restricted cash	2,979,207	-4,531,108
Issuance of member capital	'	'
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	15,547,673	23,321,925
NET INCREASE IN CASH AND CASH EQUIVALENTS	-5,366,494	7,054,538
Cash and cash equivalents	'	'
BEGINNING OF PERIOD	33,449,793	27,497,044
END OF PERIOD	28,083,299	34,551,582
Parent [Member]	'	'
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net income	-1,901,170	67,134
Adjustments to reconcile net income (loss) to cash flows from operating activities:	'	'
(Equity) loss of subsidiaries	-2,631,557	-5,526,115
Life settlements - change in fair value	0	0
Amortization of deferred financing and issuance costs	847,236	393,477
Deferred income taxes	-954,858	563,874
Preferred stock issued for dividends	192,340	83,702
(Increase) in operating assets:	'	'
Other assets	-15,947,713	-14,274,237
Increase in operating liabilities:	'	'
Accounts payable and other accrued expenses	713,785	844,042
NET CASH FLOWS USED IN OPERATING ACTIVITIES	-19,681,937	-17,848,123
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Investment in life settlements	'	'
Proceeds from settlement of life settlements	'	'
NET CASH FLOWS USED IN INVESTING ACTIVITIES	'	'
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Net proceeds from revolving credit facility	'	'
Payments for redemption of Series I Secured notes payable	'	'
Proceeds from issuance of debentures	18,365,657	23,850,794
Payments for redemption of preferred stock	'	-186,669
Payments for issuance and redemption of Renewable Secured Debentures	-4,928,888	-2,303,268
Proceeds (payments) from restricted cash	'	'
Issuance of member capital	'	'
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	13,436,769	21,360,857
NET INCREASE IN CASH AND CASH EQUIVALENTS	-6,245,168	3,512,734
Cash and cash equivalents	'	'
BEGINNING OF PERIOD	32,711,636	25,035,579
END OF PERIOD	26,466,468	28,548,313
Guarantor Subsidiary [Member]	'	'
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net income	2,631,557	5,574,635
Adjustments to reconcile net income (loss) to cash flows from operating activities:	'	'
(Equity) loss of subsidiaries	-3,037,009	-5,882,414
Life settlements - change in fair value	0	0
Amortization of deferred financing and issuance costs	166,946	272,505
Deferred income taxes	'	'
Preferred stock issued for dividends	'	'
(Increase) in operating assets:	'	'
Other assets	-15,248,357	-10,700,326
Increase in operating liabilities:	'	'
Accounts payable and other accrued expenses	229,443	131,527
NET CASH FLOWS USED IN OPERATING ACTIVITIES	-15,257,420	-10,604,073
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Investment in life settlements	'	'
Proceeds from settlement of life settlements	'	'
NET CASH FLOWS USED IN INVESTING ACTIVITIES	'	'
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Net proceeds from revolving credit facility	'	'
Payments for redemption of Series I Secured notes payable	-868,303	-1,507,824
Proceeds from issuance of debentures	'	'
Payments for issuance and redemption of Renewable Secured Debentures	'	'
Proceeds (payments) from restricted cash	1,070,000	1,469,676
Issuance of member capital	15,934,397	'
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	16,136,094	14,145,877
NET INCREASE IN CASH AND CASH EQUIVALENTS	878,674	3,541,804
Cash and cash equivalents	'	'
BEGINNING OF PERIOD	738,157	2,461,465
END OF PERIOD	1,616,831	6,003,269
Non-Guarantor Subsidiaries [Member]	'	'
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net income	3,037,009	5,833,894
Adjustments to reconcile net income (loss) to cash flows from operating activities:	'	'
(Equity) loss of subsidiaries	'	'
Life settlements - change in fair value	11,358,913	11,494,725
Amortization of deferred financing and issuance costs	-660,525	427,765
Deferred income taxes	'	'
Preferred stock issued for dividends	'	'
(Increase) in operating assets:	'	'
Other assets	'	669,198
Increase in operating liabilities:	'	'
Accounts payable and other accrued expenses	334,598	315,187
NET CASH FLOWS USED IN OPERATING ACTIVITIES	-8,647,831	-4,248,681
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Investment in life settlements	-8,271,203	-9,913,049
Proceeds from settlement of life settlements	'	1,490,000
NET CASH FLOWS USED IN INVESTING ACTIVITIES	-8,271,203	-8,423,049
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Net proceeds from revolving credit facility	'	8,000,000
Payments for redemption of Series I Secured notes payable	'	'
Proceeds from issuance of debentures	'	'
Payments for issuance and redemption of Renewable Secured Debentures	'	'
Proceeds (payments) from restricted cash	1,909,207	-6,000,784
Issuance of member capital	15,009,827	'
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	16,919,034	12,671,730
NET INCREASE IN CASH AND CASH EQUIVALENTS	'	'
Cash and cash equivalents	'	'
BEGINNING OF PERIOD	'	'
END OF PERIOD	'	'
Eliminations [Member]	'	'
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net income	-5,668,566	-11,408,529
Adjustments to reconcile net income (loss) to cash flows from operating activities:	'	'
(Equity) loss of subsidiaries	5,668,566	11,408,529
Life settlements - change in fair value	0	0
Amortization of deferred financing and issuance costs	'	'
Deferred income taxes	'	'
Preferred stock issued for dividends	'	'
(Increase) in operating assets:	'	'
Other assets	30,944,224	24,856,539
Increase in operating liabilities:	'	'
Accounts payable and other accrued expenses	'	'
NET CASH FLOWS USED IN OPERATING ACTIVITIES	30,944,224	24,856,539
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Investment in life settlements	'	'
Proceeds from settlement of life settlements	'	'
NET CASH FLOWS USED IN INVESTING ACTIVITIES	'	'
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Net proceeds from revolving credit facility	'	'
Payments for redemption of Series I Secured notes payable	'	'
Proceeds from issuance of debentures	'	'
Payments for issuance and redemption of Renewable Secured Debentures	'	'
Proceeds (payments) from restricted cash	'	'
Issuance of member capital	-30,944,224	'
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	-30,944,224	-24,856,539
NET INCREASE IN CASH AND CASH EQUIVALENTS	'	'
Cash and cash equivalents	'	'
BEGINNING OF PERIOD	'	'
END OF PERIOD	'	'

Guarantees_of_Secured_Debentur5

Guarantees of Secured Debentures (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014
Guarantees of secured debentures (Textual)	'
Debentures offer for sale	$178,289,000
Maximum rate of return on equity fund amount	18.00%
Secured Debentures [Member]	'
Guarantees of secured debentures (Textual)	'
Debentures offer for sale	$250,000,000

Concentrations_Details

Concentrations (Details)	Mar. 31, 2014	Dec. 31, 2013
Company A [Member]	'	'
Summary of the face value of insurance contracts with specific life insurance companies	'	'
Face value percentage of insurance contracts with specific life insurance companies	15.98%	16.58%
Company B [Member]	'	'
Summary of the face value of insurance contracts with specific life insurance companies	'	'
Face value percentage of insurance contracts with specific life insurance companies	11.13%	11.34%

Concentrations_Details_1

Concentrations (Details 1)	Mar. 31, 2014	Dec. 31, 2013
California [Member]	'	'
Summary of the number of insurance contracts held in specific states exceeding 10% of the total face value held by the Company	'	'
Percentage of insurance contracts held in specific states	27.97%	28.14%
Florida [Member]	'	'
Summary of the number of insurance contracts held in specific states exceeding 10% of the total face value held by the Company	'	'
Percentage of insurance contracts held in specific states	15.38%	15.59%
New York [Member]	'	'
Summary of the number of insurance contracts held in specific states exceeding 10% of the total face value held by the Company	'	'
Percentage of insurance contracts held in specific states	10.84%	10.65%

Concentration_Details_Textual

Concentration (Details Textual)	3 Months Ended
	Mar. 31, 2014
Concentration [Textual]	'
Description of issuance contracts with specific life insurance companies and contracts held in specific states	'Exceeding 10% of the total face value